Clinical Factors Affecting Thyroid Hormone Action and Treatment Outcome of Thyroid Diseases by Beukhof, C.M. (Carolien)
Clinical Factors A ecting Thyroid Horm
one Action and Treatm
ent O
utcom
e of Thyroid Diseases      Carolien M
. Beukhof    
Clinical Factors A ecting 
Thyroid Hormone Action 
and Treatment Outcome 
of Thyroid Diseases
Carolien M. Beukhof
Carolien M. Beukhof started 
undergraduate medical training at 
Erasmus University in Rotterdam. 
Following her junior clinical 
internships in Ghana, Africa and 
Melbourne, Australia, Carolien 
became resident in Internal 
Medicine at Sint Franciscus 
Gasthuis, Rotterdam, where she 
was supervised by A.P. Rietveld MD.
In 2011, she received the highest 
score of her year for the Dutch 
internal medicine exam, organized 
by the Dutch Society of Internal 
Medicine. Carolien continued her 
residency at Erasmus Medical 
Center, under the supervision of 
Prof. J.L.C.M. van Saase and Dr. 
S.C.E Klein Nagelvoort-Schuit. 
During her training to become an 
internist-endocrinologist, Carolien 
started her PhD project under the 
supervision of Prof. R.P. Peeters and 
Prof. W.W. de Herder. She was also 
active as a member of the board of 
the Young Dutch Society of Internal 
Medicine and was the chair of 
the internal residents at Erasmus 
Medical Center. During her work 
as an internist-endocrinologist at 
Flevoziekenhuis  and currently at 
Zaans Medical Center, Carolien 
finished her PhD dissertation.
Clinical Factors A ecting Thyroid Horm
one Action and Treatm
ent O
utcom
e of Thyroid Diseases      Carolien M
. Beukhof    
li i l F t rs  ti  
r i  r  ti  
 r t t t  
f r i  is s s
Carolien . Beukhof
Carolien M. Beukhof started 
undergraduate medical training at 
Erasmus University in Rotterdam. 
Following her junior clinical 
internships in Ghana, Africa and 
Melbourne, Australia, Carolien 
became resident in Internal 
Medicine at Sint Franciscus 
Gasthuis, Rotterdam, where she 
was upervised by A.P. Rietveld MD.
In 201 , she received the highest 
score of her year for the Dutch 
internal medicine exam, organized 
by the Dutch Society of Internal 
Medicine. Carolien continued her 
residency at Erasmus Medical 
Center, under the supervision of 
Prof. J.L.C.M. van Sa se and Dr. 
S.C.E Klein Nagelvo rt-Schuit. 
During her training to become an 
internist-endocrinologist, Carolien 
started her PhD project under the 
supervision of Prof. R.P. Pe ters and 
Prof. W.W. de Herder. She was also 
active as a member of the board of 
the Young Dutch Society of Internal 
Medicine and was the chair of 
the internal residents at Erasmus 
Medical Center. During her work 
as an internist-endocrinologist at 
Flevoziekenhuis and currently at 
Za ns Medical Center, Carolien 
finished her PhD dis ertation.
Clinical Factors A ecting Thyroid Horm
one Action and Treatm
ent O
utcom
e of Thyroid Diseases      Carolien M
. Beukhof    
 CLINICAL FACTORS AFFECTING THYROID 
HORMONE ACTION AND TREATMENT 
OUTCOME OF THYROID DISEASES
Carolien M. Beukhof 
15689-CBeukhof_BNW.indd   1 05-10-18   09:55
 Clinical Factors Affecting Thyroid Hormone Action and Treatment Outcome 
of Thyroid Diseases
Carolien M. Beukhof, Erasmus University Rotterdam
Printing of this thesis was supported by: 
Angiocare, Cablon Medical, ChipSoft, Ipsen and MML-Medical 
ISBN:  978-94-6375-049-3
Cover:  Hugo Loomeyer
Layout: Nikki Vermeulen - Ridderprint BV
Printing: Ridderprint BV - www.ridderprint.nl
Copyright © 2018 Carolien Beukhof, Rotterdam, The Netherlands 
All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval 
system of any nature, or transmitted in any form or by any means, without permission 
from the author, or when appropriate, from the publishers of the publications. 
15689-CBeukhof_BNW.indd   2 05-10-18   09:55
 Clinical Factors Affecting Thyroid Hormone Action 
and Treatment Outcome of Thyroid Diseases
Klinische factoren van invloed op schildklierhormoonactie en de 
behandeluitkomst van schildklierziekten
Proefschrift
Ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof. dr. R.C.M.E. Engels
en volgens besluit van het College van Promoties. 
De openbare verdediging zal plaatsvinden op 
vrijdag 14 december 2018 om 13.30 uur
door 
Carolien M. Beukhof 
geboren te Groningen 
 
15689-CBeukhof_BNW.indd   3 05-10-18   09:55
PROMOTIECOMMISSIE 
Promotors   Prof. dr. R.P. Peeters 
   Prof. dr. W.W. de Herder 
Overige leden:  Prof. dr. F.A. Verburg
   Prof. dr. R.H.J. Mathijssen 
   Prof. dr. J.L.C.M. van Saase
In memoriam: Prof. dr. T.J. Visser
15689-CBeukhof_BNW.indd   4 05-10-18   09:55
Voor Jaap en Thomas
15689-CBeukhof_BNW.indd   5 05-10-18   09:55
15689-CBeukhof_BNW.indd   6 05-10-18   09:55
CONTENTS
Chapter 1  General introduction and aims of the thesis 9 
 
 Clinical factors affecting thyroid hormone metabolism 
Chapter 2  Selenium status is positively associated with bone  23
 mineral density in healthy aging European men
Chapter 3 Sorafenib-induced changes in thyroid hormone levels   39
 in patients treated for hepatocellular carcinoma
Chapter 4  Effects of thyrotropin on peripheral thyroid hormone  59
 metabolism and serum lipids
 Consequences of thyroid hormone action 
Chapter 5 Effects of thyroid hormone on urinary concentrating  77
 ability
Chapter 6 Serum microRNA profiles in athyroid patients on and  89
 off levothyroxine therapy
 Clinical factors affecting treatment outcome of thyroid  
 disease: medullary thyroid carcinoma 
Chapter 7  Peptide receptor radionuclide therapy in patients with  105
 medullary thyroid carcinoma: predictors and pitfalls
Chapter 8  Slipped capital femoral epiphysis as manifestation of  121
 a rare endocrinological disease 
Chapter 9  Summarizing discussion and future perspectives 129
 Summary 143
 Nederlandse samenvatting  145
 List of publications  149
 PhD portfolio  150
 Acknowledgements/Dankwoord  153
15689-CBeukhof_BNW.indd   7 05-10-18   09:55
15689-CBeukhof_BNW.indd   8 05-10-18   09:55
General introduction and 
aims of the thesis
1CHAPTER
15689-CBeukhof_BNW.indd   9 05-10-18   09:55
15689-CBeukhof_BNW.indd   10 05-10-18   09:55
GENERAL INTRODUCTION AND AIMS | 11
1GENERAL INTRODUCTION 
Thyroid hormones (TH) are crucial for the function of almost every organ 
system in the human body. Thyroid disorders are one of the most common 
endocrine diseases. Too little TH (hypothyroidism) results in fatigue, weight 
gain, cold intolerance, constipation, myopathy and also dyslipidemia and 
changes in renal function. Too much TH secretion (hyperthyroidism) can 
result in weight loss, heat intolerance, frequent bowel movements and 
psychological changes (1). Both severe hypo- and hyperthyroidism can 
eventually result in death if untreated (1). Also subclinical changes in thyroid 
function are associated with adverse clinical effects such as atrial fibrillation 
(2), osteoporosis (3), dyslipidemia (4) and atherosclerosis (5). In pregnancy 
subclinical TH disturbances are associated with pregnancy complications 
such as an increased risk of prematurity and preeclampsia (6) as well as a 
lower offspring IQ (7). 
Hypothalamic-pituitary-thyroid axis
Serum TH levels are regulated within a narrow window. TH synthesis by the 
thyroid gland is controlled by the hypothalamic-pituitary-thyroid axis (HPT-
axis) (Figure 1). 
Thyroid
T4T3
Hypothalamus
+
TRH
+
Pituitary
TSH
Liver / Muscle
T4
T3
T4
T3
+
T4
T3
FIGURE 1 
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Hypothalamic release of thyrotropin-releasing hormone (TRH) results in 
subsequent release of thyroid stimulating hormone (Thyrotropin, TSH) by 
the anterior pituitary. TSH binding to the TSH receptor (TSHR), a G protein-
coupled receptor, activates the cyclic Adenosine MonoPhosphate (cAMP) 
pathway and stimulates TH production and secretion by the thyroid gland 
(8). However, TSHR have been shown in skeletal muscle, bone, fat tissue and 
liver, indicating that TSH can also have extrathyroidal effects (9-11).
Negative feedback on the HPT-axis is dependent on intracellular T3 levels in 
the pituitary and hypothalamus, which is mainly derived by local conversion 
of T4 to T3 by type 2 deiodinase (D2) in these tissues (12, 13) (see paragraph 
thyroid hormone metabolism). Somatostatin also exploits an inhibitory role 
in the TSH secretion by pituitary. Somatostatin analogues have been found 
to reduce serum TSH (14).
Thyroid hormones and regulation of thyroid hormone action 
Thyroid hormone metabolism
TH is composed of an inner and outer phenyl ring with iodine atoms attached 
at the 3, 3’, 5 and 5’ positions. Therefore, adequate intake of iodine via 
food is essential for normal TH production. Thyroxine (T4) is produced by 
the thyroid gland and has four iodine atoms. Removal of one iodine atom 
from the outer phenyl ring by intracellularly localized deiodinases results in 
activation of TH to triiodothyronine (T3), whereas removal of an iodine from 
the inner ring results in the production of the inactive metabolite reverse 
triiodothyronine (rT3) (15) (Figure 2).
T3 is the main biologically active TH and has only one iodine atom in the 
outer phenyl ring. The thyroid predominantly produces T4 and only a 
small percentage of total circulating T3. Circa 20% of serum T3 is derived 
from thyroidal secretion of T3, whereas the remaining 80% is produced by 
peripheral tissues such as the liver (peripheral TH metabolism). T4 can be 
activated into T3 by deiodinase type 1 and type 2 (D1 and D2), whereas 
inactivation of TH is mediated mainly via degradation of T4 and T3 by 
deiodinase type 3 (D3) into rT3 and diiodothyronine (T2)(16). 
All three deiodinases contain a selenocysteine group in their catalytic centre 
and therefore belong to the class of selenoproteins. Selenoproteins are 
not only important in TH homeostasis but are also important in antioxidant 
defence (16, 17). For the biosynthesis of selenoproteins, selenium (Se), a 
nutritional trace element, is essential. Patients with severely compromised 
selenoprotein biosynthesis or massive Se deficiency show a variety of 
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1endocrine defects including abnormal thyroid function and delayed or impaired bone formation (18-20). 
Many conditions, including long-term subclinical hyperthyroidism (21) and 
critical illness (22), influence peripheral thyroid hormone metabolism. Also 
several drugs, such as corticosteroids and amiodarone, affect the activity 
of deiodinases (16). Furthermore, thyrosine kinase inhibitors (TKI), which 
are currently used to treat hepatocellular carcinoma (HCC), differentiated 
thyroid carcinoma (DTC) and medullary thyroid carcinoma (MTC), have been 
implicated to alter peripheral TH metabolism (23). 
Thyroid hormone metabolism
T4
rT3T3
D1, D2 D3, D1
T2
D1, D2D3, D1
FIGURE 2
Thyroid hormone receptors 
TH action is mediated via T3 receptors in the nucleus (15). Two thyroid 
hormone receptors (TR) with different isoforms have been identified, of 
which TR-α1, TR-β1 and TR-β2 are the T3 binding isoforms. These TRs have 
a tissue specific distribution. TR-α1 is mainly expressed in the heart, brain, 
skeletal muscles and gastrointestinal tract. TR-β1 is predominantly expressed 
in brain, liver and kidney, whereas TR-β2 has a more restrictive expression 
pattern in hypothalamus, pituitary and retina. TR selective agents have been 
developed in an attempt to mediate tissue-specific actions of TH. 
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Thyroid hormone transporters 
The intracellular concentration and subsequent receptor binding of T3 is 
influenced by several mechanisms. The in- and efflux of TH over the cell 
membrane depends on serum concentrations of T3 and T4 and the activity 
of TH transporters, such as monocarboxylate transporters 8 and 10 (MCT8 
and MCT10) and organic anion transporting polypeptide 1C1 (OATP1C1) 
(24). MCT8 is expressed in neurons in the brain and is the main transporter 
of the blood-brain barrier (25). MCT8 is also expressed in several other 
tissues including the liver, the kidney and the heart (26). Mutations in MCT8 
result in the Allan-Herndon-Dudley syndrome, which is characterized by a 
severe neurological syndrome of X-linked mental retardation and peripheral 
thyrotoxicosis. Patients have low serum T4, elevated serum T3 levels and 
a normal or slightly elevated TSH (27). MCT10 is highly expressed in the 
skeletal muscles, kidney, pancreas and intestine (28). It appears to facilitate 
T3 uptake and efflux more than T4 (29). The clinical relevance of MCT10 
remains to be established, since no patients with mutations have been 
identified. OATP1C1 facilitates T4 uptake into the astrocytes in the brain, 
and with subsequent conversion into T3 by D2 (30). 
Treatment of thyroid hormone disorders 
Hyperthyroidism 
Excess of TH secretion by the thyroid results in the clinical syndrome 
“hyperthyroidism”. The most common cause of primary hyperthyroidism is 
Graves’ disease, which is an autoimmune disease caused by stimulating TSH 
receptor antibodies (TSHR-Ab). Treatment consists of antithyroid drugs and 
in case of relapse, radioactive iodine treatment is often used successfully in 
patients without Graves’ ophthalmopathy. Surgery is reserved for patients 
with high risk eye disease, but is rarely necessary (31). 
Other common causes of primary hyperthyroidism are toxic multinodular 
goiter and toxic adenoma. Due to high relapse risk after discontinuation 
of antithyroid drugs, radioactive iodine therapy is the first line treatment 
for these patients. In contrast, in patients with thyroiditis, another cause of 
hyperthyroidism, only requires supportive care with β blockers and painkiller, 
as the thyrotoxicosis spontaneously resolves in most patients (31). 
Hypothyroidism 
Hypothyroidism on the other hand is characterized by low TH levels. In most 
patients with primary hypothyroidism, the disease is irreversible due to 
15689-CBeukhof_BNW.indd   14 05-10-18   09:55
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1autoimmune destruction of the thyroid (Hashimoto’s disease) and lifelong TH replacement therapy is required. Oral administration of synthetic thyroxine, 
levothyroxine (LT4) is the standard treatment and titrated to normalize serum 
TSH in order to ameliorate symptoms.
Subgroups of patients with hypothyroidism have residual symptoms despite 
TH replacement therapy (32). Due to a lack of endogenous T3 production by 
the thyroid, substitution with LT4 monotherapy generally results in higher 
free T4 (FT4) and lower free T3 (FT3) levels and consequently altered T3/
T4 ratios compared to the healthy population (33). TH transporters and 
intracellular deiodinases demonstrate tissue specific regulation, therefore 
LT4 monotherapy may not restore euthyroidism in all peripheral tissues (34). 
However, at present, combined LT4 and T3 treatment continues to be a 
matter of debate and the beneficial effects of LT4 and T3 combinations have 
not been demonstrated (35).
Thyroid carcinoma 
Differentiated thyroid cancer
DTC is the most frequent endocrine malignancy and can be treated by 
thyroidectomy and subsequent radioactive iodine 131I ablation (36). 
Consequently, these patients completely lack remaining functional thyroid 
tissue and thyroidal T4 and T3 secretion. As patients are usually treated with 
LT4 monotherapy, serum T3 in these patients is derived from the conversion 
of T4 in peripheral tissues. During follow-up of DTC, patients undergo a 
recombinant human TSH (rhTSH) stimulation test as part of a dynamic risk 
stratification. 
In patients with progressive metastasized disease who become refractory 
for radioactive iodine treatment, TKIs, such as sorafenib and lenvatinib, can 
be used for treatment (37). TKIs have antiangiogenic, antiproliferative and 
proapoptotic effects via multiple effector mechanisms, such as inhibition of 
the vascular endothelial growth factor receptor (38). It has been reported 
that LT4 treatment needs to be increased in hypothyroid patients treated 
with TKIs, due to an increase in TSH levels. This is presumably caused by 
enhanced peripheral degradation of TH by D3 (23). 
Medullary thyroid carcinoma 
MTC, originating from calcitonin (CT)-producing parafollicular C cells, is a rare 
form of thyroid cancer that accounts for less than 5% of thyroid carcinomas 
(39). Limited systemic treatment options are available for locally irresectable 
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tumor and/or distant metastases (40, 41). TKIs such as vandetanib and 
cabozantinib, improve progression-free survival (PFS), but unfortunately not 
overall survival (OS). However, grade 3 or 4 adverse events occur in 33-44% 
of TKI treated patients (41, 42). 
AIMS OF THE THESIS
The aim of this thesis has been to study clinical factors affecting TH action as 
well as its consequences. In addition, we have explored a novel therapeutic 
modality for medullary thyroid carcinoma. 
TH hormone metabolism is affected by many clinical factors. An altered 
metabolism of TH due to low Se status has been proposed as a mechanism 
for the age-dependent changes in thyroid parameters (16, 43-49). In 2012, 
a positive association between Se status and bone mineral density (BMD) 
was described in postmenopausal women (45). No data on the association of 
Se status and BMD in elderly men were available at that time. For that reason, 
we have investigated the association between Se status, thyroid function 
tests (TFT) (e.g. TSH, FT4, T3, rT3) and BMD in a population of 378 elderly 
men (chapter 2). 
The pathogenesis of TKI-induced changes in TH levels and metabolism has 
not been fully elucidated (50, 51). Therefore in chapter 3 we aimed to further 
unravel the effects of sorafenib on different aspects of TH homeostasis, such 
as direct effects on the thyroid, sensitivity of the HPT-axis and peripheral TH 
metabolism, by performing detailed TFT in 57 patients with HCC, as well as 
in-vitro cellular T3-uptake experiments. 
The TSHR has not only been found on the surface of thyrocytes but also in a 
variety of other cell types including adipocytes (52). Epidemiological (5, 53-
58) and experimental studies (10, 11) suggest that TSH has direct effects on 
serum lipids. Although TSH has been shown to increase hepatic conversion 
of T4 to T3 in perfused rat liver (59), direct effects of TSH on peripheral TH 
metabolism have not been reported in humans. To address this, we have 
examined the effect of exogenous rhTSH on serum lipids and peripheral TH 
metabolism in 81 patients, on stable LT4 maintenance doses, who had total 
thyroidectomy and radioactive 131I treatment for of DTC (chapter 4).
Urinary concentration studies in hypothyroidism have been compared to 
healthy controls but paired analyses within the same patient are lacking 
(60). In chapter 5 we have investigated the effects of short term severe 
hypothyroidism on urine concentration ability of the kidney, in nine patients 
with hypothyroidism, before and after withdrawal of LT4 treatment. 
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1Serum TSH is currently the best available marker in patients with hypothyroidism to titrate LT4 dosing. However, TSH reflects euthyroidism 
at the pituitary level, but may not be representative for other target tissues. 
Therefore, new markers are warranted. MicroRNAs (miRNAs) are non-coding 
RNA molecules that show a tissue-specific expression. In chapter 6 we have 
investigated the changes in miRNA profiles in hypothyroid patients on and 
off LT4 administration. 
For progressive metastatic MTC, treatment with TKI result in grade 3-4 
adverse events in a large number of patients. Peptide receptor radionuclide 
therapy (PRRT) with 177Lu-octreotate, targeting the carcinoma mainly via the 
somatostatin receptor 2 (SSTR2), might be a rational therapeutic approach 
(61). In chapter 7, we have systematically analyzed the results of PRRT in ten 
patients with MTC. 
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ABSTRACT
Objective 
It is still a matter of debate if subtle changes in selenium (Se) status affect 
thyroid function tests (TFTs) and bone mineral density (BMD). This is 
particularly relevant for the elderly, whose nutritional status is more vulnerable. 
Design and methods
We investigated Se status in a cohort of 387 healthy elderly men (median age 
77 yrs; inter quartile range 75-80 yrs) in relation to TFTs and BMD. Se status 
was determined by measuring both plasma selenoprotein P (SePP) and Se. 
Results
The overall Se status in our population was low normal with only 0.5% (2/387) 
of subjects meeting the criteria for Se deficiency. SePP and Se levels were 
not associated with thyroid stimulating hormone (TSH), free thyroxine (FT4), 
thyroxine (T4), triiodothyronine (T3) or reverse triiodothyronine (rT3) levels. 
The T3/T4 and T3/rT3 ratios, reflecting peripheral metabolism of thyroid 
hormone, were not associated with Se status either.
SePP and Se were positively associated with total BMD and femoral trochanter 
BMD. Se, but not SePP, was positively associated with femoral neck and ward’s 
BMD. Multivariate linear analyses showed that these associations remain 
statistically significant in a model including TSH, FT4, body mass index, 
physical performance score, age, smoking, diabetes mellitus and number of 
medication use. 
Conclusion
Our study demonstrates that Se status, within the normal European marginally 
supplied range, is positively associated with BMD in healthy aging men, 
independent of thyroid function. Thyroid function tests appear unaffected 
by Se status in this population. 
Abbreviations
B, Beta; BMD, bone mineral density; BMI, body mass index; DM, Diabetes 
Mellitus; FT4, free thyroxine; IQR, inter quartile range; N, number of subjects; 
* , p<0.05; ** , p<0.01; ***, p<0.001; rT3, reverse triiodothyronine; SD, 
standard deviation, Se, selenium; (SE), standard error; SePP, selenoprotein P; 
TFTs, thyroid function tests; TH, thyroid hormone; TSH, thyroid stimulating 
hormone; T3, triiodothyronine; T4, thyroxine
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INTRODUCTION
Selenium (Se) is a nutritional trace element that is essential for the 
biosynthesis of selenoproteins. Selenoproteins elicit important functions 
in different processes such as thyroid hormone (TH) homeostasis and 
antioxidant defence (1, 2). Patients with severely compromised selenoprotein 
biosynthesis or massive Se deficiency show a variety of endocrine defects 
including abnormal thyroid function tests (TFTs) and delayed or impaired 
bone formation (3-5). However, it is still a matter of debate if also more 
subtle changes in Se status are associated with alterations in TFTs and bone 
mineral density (BMD). This is especially important for elderly who are at risk 
for malnutrition (6).
Peripheral metabolism of TH levels is predominantly mediated by the 
selenoenzymes type 1, type 2, and type 3 deiodinase (D1-3), which all 
contain a selenocysteine in their catalytic centre. An altered metabolism of 
TH due to low Se status has been proposed as a mechanism for the age-
dependent changes in thyroid parameters (1, 7-13). 
In 2012 we described a positive association between Se status and BMD in 
postmenopausal women (9). No data on the association of Se status and 
BMD in elderly men are yet available (14-16), despite the knowledge that Se 
biology and selenoprotein expression show sex-specific differences in rodent 
models and human studies (17).
For those reasons we investigated the association between Se status, TFTs 
and BMD in a population of elderly men. Se status was determined by 
measuring both selenoprotein P (SePP) and plasma Se concentrations. SePP 
is a liver-derived Se storage and transport protein and is considered the most 
reliable biomarker of Se status (18). 
MATERIALS AND METHODS
Study population
The Zoetermeer study is a cohort study conducted in clinically healthy 
independently living Caucasian elderly men between 1996 and 2000. 
The specific design and the effect of thyroid hormone concentrations on 
disease, physical function and mortality has been reported in 2005 (12). In 
brief, individuals were drawn from the municipal register of Zoetermeer, The 
Netherlands. Inclusion criteria were male sex, age at least 70 years, and a 
sufficient physical and mental status to visit the study center independently. 
The Medical Ethics Committee of the Erasmus Medical Center approved the 
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study, which included permission for additional measurements in stored 
serum and plasma samples. Four hundred and three men participated and 
gave written informed consent. 
The subjects were interviewed by the same person and medical history, 
smoking status and medication use were recorded. A total of 16 individuals 
were excluded; 6 individuals on TH replacement, 8 individuals taking the 
thyroid hormone interfering drug amiodarone, and 2 Se outliers (defined as 
SePP or Se ≥4 standard deviations from the mean). This resulted in a final 
population of 387 subjects for analysis. 
Determination of Se status
SePP and Se levels were measured in 2007 in the same plasma samples in 
parallel and blinded to the characteristics of the participants in a laboratory 
remote from the study site. A previous stability analysis showed no decline 
over time (19). Fluorescence spectroscopy was used for Se determination 
as described earlier (18). A commercial human serum standard (Sero AS, 
Billingstad, Norway) was included for standardization. SePP concentrations 
were determined by a luminometric immune assay as described (19). The 
analyses were conducted in duplicates and inter- and intra-assay variations 
were <15% during the measurements. 
Normal values for SePP and Se were determined in our previous study including 
2374 European postmenopausal woman, using the same spectroscopy and 
immune assay (9). 
Reference ranges from another Dutch study in 1987 are not comparable due 
to the use of another Se assay (20). There is no association between Se 
status and sex, but there is a positive association with age (21). Therefore, 
all analyses are adjusted for age. 
Thyroid function tests
Blood samples were collected in the morning after an overnight fast. Serum 
was separated by centrifugation and stored at −40 °C. All serum TFTs 
(thyroid stimulating hormone (TSH), free thyroxine (FT4), thyroxine (T4), 
triiodothyronine (T3) and reverse triiodothyronine (rT3) were determined 
using well-established assays as described previously (22). 
Bone Mineral Density
Total BMD was measured using dual-energy x-ray absorptiometry (DEXA) 
(Lunar, Madison, WI), as were hip BMDs at the femoral neck, trochanter, 
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and Ward’s triangle. Quality assurance for DEXA, including calibration, was 
performed every morning, using the standards provided by the manufacturer 
(12). 
Physical performance, body composition and diabetes 
mellitus
Physical performance was assessed as described by Guralnik et al. (23), 
including measurements of standing balance, walking speed and ability to 
rise from a chair. Scores of the tests as well as the summary performance 
scale were comparable with subjects of the same age group investigated by 
Guralnik et al. (12, 23).
Height and weight were measured in standing position without shoes. Body 
mass index (BMI) was calculated as the weight in kilograms divided by the 
square of the height in meters. The average of two readings was used in the 
analyses.
Hemoglobin A1c (HbA1c) and fasting glucose levels were determined (24). 
Diagnosis of new onset diabetes mellitus (DM) was based on a fasting plasma 
glucose level ≥7.0 mmol/L and HbA1c ≥6.5 percent (25). 
Statistics
Analyses were performed using SPSS version 23 (SPSS Inc, Chicago, Il). 
Normal distribution was evaluated using the Kolmogorov-Smirnov test, and 
variables that were not normally distributed underwent natural logarithmic 
transformation. Linear regression analyses were used to determine the 
associations between SePP and Se, TFTs and BMD. ANOVA analysis was used 
to present mean values for the lowest and highest Se and SePP quartiles to 
provide extra insight into the actual effects. 
Multivariate linear model was used to correct the association between Se 
status and BMD for TSH, FT4, BMI, physical performance score, smoking 
status, known and new onset DM and total number of medication use. All 
analyses were adjusted for age. A p-value <0.05 was considered significant.
RESULTS
Baseline characteristics and selenium status
The median age of the population was 77 yrs [inter quartile range (IQR) 75-80 
yrs; range 73-94yrs]. The mean SePP concentration was 3.4 mg/L (SD±0.75) 
and median Se was 92 µg/L [IQR 82-101]. Overall Se status was suboptimal, 
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but only 0.5% (2/387) of subjects met the criteria for Se deficiency (SePP < 2 
mg/L and Se < 58 µg/L) (9) (Table 1). 
Thirty one subjects with known DM and 13 patients with new onset DM were 
identified. The prevalence of 11.4% is conform the large population based 
study in the Netherlands including 1614 patients aged >70 years (26), but 
lower compared to the age and sex specific prevalence of 16% from the 
European cohorts combined (27).
 
Table 1. Baseline characteristics
Normal value N=387
Age, yrs, median [IQR] 77[75-80]
SePP, mg/L, mean (±SD)  ≥ 2.0 3.44(±0.75)
Se, µg/L, median [IQR]  ≥ 58 91.9[82.0-101.1]
TSH, mU/L, median [IQR] 0.4-4.3 0.95[0.60-1.43]
FT4, pmol/L, mean (±SD) 11-25 16.6(±3.1)
Total BMD, mg/cm2, mean (±SD) 1169.1(±98.0)
Smoking, no (%) 66(17.1%)
Physical performance score, median [IQR] 0-12 9[7-10]
BMI, kg/m2 , mean (±SD) 18.5-25.0 25.4(±3.0)
DM, no (%) 44(11.4%)
Medication, no, median [IQR] 1[0-2]
BMD, bone mineral density; BMI, body mass index; DM, diabetes mellitus pre-existent and new 
onset; FT4, free thyroxine; IQR, inter quartile range; medication, total number of medication, N, 
total number of subjects studied; no, number; yrs, years; SD, standard deviation; Se, Selenium; 
SePP, selenoprotein P; TSH, thyroid stimulating hormone
Thyroid function tests
SePP and Se levels were not associated with TFTs (Table 2). TH levels depend 
not only on the activities of TH-metabolizing enzymes but also, among other 
things, on thyroid function and plasma TH-binding capacity. Therefore, 
ratios between plasma TH’s are thought to better reflect tissue deiodinase 
activities (28). However, T3/T4, T3/rT3 and rT3/T4 ratios were not associated 
with Se status either (Table 2). 
Bone mineral density 
SePP and Se were positively associated with total BMD and femoral trochanter 
BMD. Se, but not SePP, was positively associated with femoral neck BMD and 
Ward’s triangle BMD (Table 3). We subsequently constructed a multivariate 
linear regression model to control for a number of potentially interfering 
15689-CBeukhof_BNW.indd   28 05-10-18   09:55
SELENIUM STATUS AND BONE MINERAL DENSITY | 29
2
Ta
bl
e 
2.
 A
ss
oc
ia
tio
ns
 b
et
w
ee
n 
se
le
ni
um
 st
at
us
 a
nd
 th
yr
oi
d 
fu
nc
tio
n 
te
st
s
Se
PP
Se
Li
ne
ar
 re
gr
es
si
on
Q
ua
rt
ile
s
Li
ne
ar
 re
gr
es
si
on
Q
ua
rt
ile
s
TF
Ts
No
rm
al
 v
al
ue
B(
SE
)
p
Q
1 
M
ea
n(
SE
)
Q
4 
M
ea
n(
SE
)
B(
SE
)
p
Q
1 
M
ea
n(
SE
)
Q
4 
M
ea
n(
SE
)
TS
H,
 m
U/
L
0.
4-
4.
3
<0
.0
1(
0.
07
)
0.
95
1.
24
(0
.1
0)
1.
14
(0
.1
0)
<0
.0
1(
0.
03
)
0.
98
1.
23
(0
.1
0)
1.
30
(0
.1
0)
FT
4,
 p
m
ol
/L
 
11
-2
5
0.
11
(0
.2
1)
0.
60
16
.4
(0
.3
3)
16
.7
(0
.3
2)
0.
01
(0
.0
1)
0.
11
16
.2
(0
.3
2)
16
.7
(0
.3
2)
T4
, n
m
ol
/L
58
-1
28
1.
73
(1
.0
7)
0.
11
79
.1
(1
.6
8)
81
.3
(1
.6
4)
0.
03
(0
.0
5)
0.
45
80
.1
(1
.6
6)
79
.2
(1
.6
5)
T3
, n
m
ol
/L
 
1.
43
-2
.5
1
<0
.0
1(
0.
02
)
0.
92
1.
45
(0
.0
3)
1.
41
(0
.0
2)
<0
.0
1(
0.
01
)
0.
80
1.
40
(0
.0
2)
1.
41
(0
.0
2)
rT
3,
 n
m
ol
/L
 
0.
14
-0
.3
4
0.
01
(0
.0
1)
0.
22
0.
32
(0
.0
1)
0.
33
(0
.0
1)
<0
.0
1(
0.
01
)
0.
96
0.
33
(0
.0
1)
0.
32
(0
.0
1)
T3
/T
4 
x1
00
1.
42
-3
.0
5
-0
.0
5(
0.
03
)
0.
11
1.
95
(0
.0
5)
1.
78
(0
.0
5)
<0
.0
1(
0.
01
)
0.
95
1.
82
(0
.0
5)
1.
89
(0
.0
5)
T3
/rT
3 
3.
12
-1
3.
03
-0
.1
5(
0.
11
)
0.
30
5.
01
(0
.1
6)
4.
56
(0
.1
6)
<0
.0
1(
0.
01
)
0.
95
4.
69
(0
.1
6)
4.
72
(0
.1
6)
rT
3/
T4
x1
00
 
0.
15
-0
.4
4
<0
.0
1(
0.
01
)
0.
97
0.
41
(0
.0
1)
0.
41
(0
.0
1)
<0
.0
1(
0.
01
)
0.
84
0.
42
(0
.0
1)
0.
42
(0
.0
1)
Th
e 
re
su
lts
 (B
(S
E)
 a
nd
 c
or
re
sp
on
di
ng
 p
-v
al
ue
s)
 o
f t
he
 li
ne
ar
 re
gr
es
sio
n 
an
al
ys
es
 o
f S
eP
P 
an
d 
Se
 le
ve
ls 
ve
rs
us
 va
rio
us
 T
FT
s a
re
 sh
ow
n.
 In
 a
dd
iti
on
, 
m
ea
n 
va
lu
es
 fo
r t
he
 lo
w
es
t a
nd
 h
ig
he
st
 S
e 
an
d 
Se
PP
 q
ua
rt
ile
s 
ar
e 
pr
es
en
te
d 
to
 p
ro
vi
de
 e
xt
ra
 in
sig
ht
 in
to
 th
e 
ac
tu
al
 e
ffe
ct
s.
 
B,
 B
et
a;
 F
T4
, f
re
e 
th
yr
ox
in
e;
 rT
3,
 re
ve
rs
e 
tri
io
do
th
yr
on
in
e;
 S
e,
 S
el
en
iu
m
; (
SE
), 
st
an
da
rd
 e
rro
r; 
Se
PP
, s
el
en
op
ro
te
in
 P
; T
FT
s,
 th
yr
oi
d 
fu
nc
tio
n 
te
st
s;
 
TS
H,
 th
yr
oi
d 
st
im
ul
at
in
g 
ho
rm
on
e;
 T
3,
 tr
iio
do
th
yr
on
in
e;
 T
4,
 th
yr
ox
in
e;
 Q
1,
 fi
rs
t q
ua
rt
ile
; Q
4,
 fo
ur
th
 q
ua
rt
ile
15689-CBeukhof_BNW.indd   29 05-10-18   09:55
30 | CHAPTER 2
Ta
bl
e 
3.
 S
el
en
iu
m
 st
at
us
 a
nd
 a
ss
oc
ia
tio
n 
w
ith
 b
on
e 
m
in
er
al
 d
en
si
ty
BM
D 
m
g/
cm
2
Se
PP
 
Li
ne
ar
 re
gr
es
si
on
 
M
ul
tiv
ar
ia
te
 re
gr
es
si
on
Q
ua
rt
ile
s
B(
SE
) U
na
dj
us
te
d
p 
Un
ad
ju
st
ed
B(
SE
) A
dj
us
te
d
p 
Ad
ju
st
ed
Q
1 
M
ea
n(
SE
)
Q
4 
M
ea
n(
SE
)
To
ta
l
15
.5
7(
6.
68
)
0.
02
*
13
.3
6 
(6
.0
9)
0.
03
*
11
47
.6
(1
0.
1)
11
87
.6
(9
.9
)
Fe
m
or
al
 n
ec
k 
13
.4
2(
10
.1
5)
0.
14
10
.7
2(
9.
91
)
0.
21
85
5.
5(
15
.3
)
89
9.
9(
15
.1
)
Fe
m
or
al
 tr
oc
ha
nt
er
26
.3
5(
10
.2
3)
0.
01
*
23
.8
0(
9.
52
)
0.
01
*
81
2.
7(
 1
5.
4)
88
1.
7(
15
.2
)
Fe
m
or
al
 w
ar
d
16
.2
2(
11
.3
0)
0.
08
12
.5
5(
11
.1
4)
0.
15
68
8.
6(
17
.1
)
73
6.
4(
16
.8
)
BM
D 
 m
g/
cm
2
Se
Li
ne
ar
 re
gr
es
si
on
M
ul
tiv
ar
ia
te
 re
gr
es
si
on
Q
ua
rt
ile
s
B(
SE
) U
na
dj
us
te
d
p 
Un
ad
ju
st
ed
B(
SE
) A
dj
us
te
d
p 
Ad
ju
st
ed
Q
1 
M
ea
n(
SE
)
Q
4 
M
ea
n(
SE
)
To
ta
l
0.
87
(0
.2
8)
0.
00
1*
*
0.
81
(0
.2
6)
0.
00
1*
*
11
55
.6
(9
.9
)
11
95
.6
(9
.8
)
Fe
m
or
al
 n
ec
k 
1.
36
(0
.4
2)
0.
00
1*
*
1.
24
(0
.4
1)
0.
00
2*
*
84
8.
6(
15
.0
)
92
4.
5(
14
.7
)
Fe
m
or
al
 tr
oc
ha
nt
er
1.
50
(0
.4
3)
<0
.0
01
**
*
1.
40
(0
.4
0)
<0
.0
01
**
*
81
3.
9(
15
.0
)
90
3.
6(
14
.8
)
Fe
m
or
al
 w
ar
d
1.
38
(0
.4
7)
0.
00
3*
*
1.
25
(0
.4
7)
0.
00
6*
*
67
8.
4(
16
.7
)
76
0.
3(
16
.5
)
Th
e 
re
su
lts
 (B
(S
E)
 a
nd
 c
or
re
sp
on
di
ng
 p
-v
al
ue
s)
 o
f t
he
 li
ne
ar
 re
gr
es
sio
n 
an
al
ys
es
 o
f S
eP
P 
an
d 
Se
 le
ve
ls 
ve
rs
us
 B
M
D 
ar
e 
sh
ow
n.
 M
ul
tiv
ar
ia
te
 li
ne
ar
 
m
od
el
 w
as
 u
se
d 
to
 c
or
re
ct
 fo
r T
SH
, F
T4
, a
ge
, B
M
I, 
ph
ys
ic
al
 p
er
fo
rm
an
ce
 sc
or
e,
 sm
ok
in
g 
st
at
us
, k
no
w
n 
an
d 
ne
w
 o
ns
et
 d
ia
be
te
s m
el
lit
us
 a
nd
 to
ta
l 
nu
m
be
r o
f m
ed
ic
at
io
n 
us
e 
(B
(S
E)
 a
dj
us
te
d 
an
d 
co
rre
sp
on
di
ng
 a
dj
us
te
d 
p-
va
lu
es
). 
M
ea
n 
va
lu
es
 fo
r t
he
 lo
w
es
t a
nd
 h
ig
he
st
 S
e 
an
d 
Se
PP
 q
ua
rt
ile
s 
ar
e 
pr
es
en
te
d 
to
 p
ro
vi
de
 e
xt
ra
 in
sig
ht
 in
to
 th
e 
ac
tu
al
 e
ffe
ct
s.
 
B,
 B
et
a;
 B
M
D,
 b
on
e 
m
in
er
al
 d
en
sit
y;
 B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 F
T4
, f
re
e 
th
yr
ox
in
e;
 S
e,
 S
el
en
iu
m
; (
SE
), 
st
an
da
rd
 e
rro
r; 
Se
PP
, s
el
en
op
ro
te
in
 P
; T
SH
, 
th
yr
oi
d 
st
im
ul
at
in
g 
ho
rm
on
e;
 Q
1,
 fi
rs
t q
ua
rt
ile
; Q
4,
 fo
ur
th
 q
ua
rt
ile
; *
 , 
p<
0.
05
; *
* ,
 p
<0
.0
1;
 **
*, 
p<
0.
00
1
15689-CBeukhof_BNW.indd   30 05-10-18   09:55
SELENIUM STATUS AND BONE MINERAL DENSITY | 31
2
factors including; TSH and FT4, as measures of (mild) thyroid dysfunction, 
BMI, which is known to be a risk factor for osteoporosis and associated 
with food intake and smoking which is described to modify the antioxidant 
effect of Se on BMD (14). The association of DM, Se status and BMD is still a 
matter of debate (29). Therefore subjects with known and new onset DM are 
included in the model. 
To account for the influence of chronic diseases and physical activity we also 
included the total number of medication use and physical performance score 
in the model. 
After additional adjustment for these factors the positive associations 
between Se status and BMD remained statistically significant (Table 3). 
DISCUSSION
In the present study we investigated Se status in healthy elderly men in 
relation to TFTs and BMD. Although elderly subjects are at increased risk 
of nutritional deficiencies, with our assay that is well suited to cover low 
SePP concentration ranges, only a few patients were Se deficient. This is an 
important finding, especially since Se deficiency is becoming increasingly 
recognized as a health risk. These results are in agreement with the vast 
majority of studies that all conclude that European subjects are marginally 
supplied and on average below the Se concentration needed for full 
expression of selenoproteins (30, 31). This is the first study to show in men 
that Se status, even within this low normal range, is positively associated 
with BMD independent of TH status. This is in concordance with our recent 
findings in elderly postmenopausal women (9).
Although an altered metabolism of TH due to low Se status has been 
proposed as a mechanism for the age-dependent changes in TFTs (7, 8), 
extensive profiling of thyroid parameters in the current study did not reveal 
any association of TFTs with Se status. Our analysis included assessment of 
T3/T4 and T3/rT3 ratios as a reflection of the peripheral metabolism of TH. 
We can therefore conclude that our previously reported association between 
FT4 and rT3 levels with physical performance and/or survival in this cohort is 
not mediated via Se status (12). The lack of association between Se status 
and TFTs in the current study is in line with a randomized controlled trial in 
elderly in which Se supplements failed to improve thyroid function (10). In 
addition, also in Se-deficient transgenic mice, the synthesis and metabolism 
of TH is surprisingly well maintained (32, 33). 
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These results are in contrast, however, with our recent study in 1144 
healthy euthyroid postmenopausal women in which Se and SePP were 
inversely associated with FT3 and FT4 and positively associated with the 
T4/T3 ratio (9). The Se status of these two populations is comparable. This 
may point towards a sex-specific difference in this interaction, in line with 
a number of other sexual dimorphisms in Se metabolism in patients as well 
as in experimental animals (17). Notably, expression of D1 strongly differed 
between male and female rodents via Se-dependent mechanisms affecting 
protein translation (34). Unfortunately, no serum rT3 levels were available 
in the previous study on postmenopausal females, which would have 
allowed for a better comparison and speculation on the differential effects 
of Se status and peripheral deiodinase activities between elderly males and 
females. Discrepancies between the two studies might also be explained by 
the relatively older age of the current male population (77.8 (±3.6) versus 
67.8 (±7.0) yrs). Older subjects may have more co-morbidities which also 
affect the degradation of TH. 
Low Se status is known to be associated with skeletal disease in patients 
with mutations in selenoproteins (selenocystein insertion sequence binding 
protein 2), Kashin-Beck osteoarthropathy and women (4, 9). Also, Se 
intake appears to be inversely associated with the risk of osteoporotic hip 
fractures (14). Women are known to be more vulnerable to osteoporosis 
(35), but our current findings demonstrate that Se status influences BMD 
in men as well. Although only two individuals had subnormal Se values, it is 
very interesting that even in a population with borderline sufficiency there 
is a significant association with bone mineral density. An effect of TH on 
BMD could be excluded as correction for thyroid status did not affect the 
observed associations between Se status and BMD. Some previous clinical 
studies in healthy women did not demonstrate an association between Se 
status and BMD, possibly due to a lack of power (77 and 107 subjects) (15, 
36). Mechanistically, SePP has been shown to transport Se to bone, and a 
receptor-mediated uptake ensures a relatively high bone Se supply even 
during Se shortage (37). In vitro studies have demonstrated an effect of Se 
on osteoblast differentiation and subsequent bone resorption by modulating 
oxidative stress (38, 39). 
Our study has a number of potential limitations. Due to the cross-sectional 
design of the study, causality of the associations found cannot be assessed. 
We cannot exclude that the voluntary participation of our subjects has 
resulted in a bias with more health-interested and thus better eating elderly 
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being enrolled. In addition, no data on vitamin D or calcium levels were 
available. In our previous paper the association of Se status and BMD was 
not influenced by vitamin D (9). To the best of our knowledge there is no 
clear evidence that plasma calcium levels are associated with Se status., 
Parathyroid hormone which reflects changes in calcium homeostasis, did 
not influence the association of Se status and BMD in previous studies 
either (9). Therefore, it is not very likely that in the current study in healthy 
ambulant men, differences in vitamin D or calcium levels have confounded or 
mediated our results. Finally, while we have shown effects on BMD, no data 
on fracture risk were available. Future studies should therefore investigate 
the relation between Se levels and fracture risk, as well as the underlying 
pathophysiological mechanisms of these observed associations.
CONCLUSIONS
Our study demonstrates that Se status within the low normal range is 
positively associated with BMD in healthy aging European men, independent 
of TH function. TFTs appear unaffected by Se status in this population. 
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ABSTRACT
Context
The pathogenesis of tyrosine kinase inhibitor-induced thyroid hormone (TH) 
alterations are still a matter of debate.
Objective
The objective of this study was to determine the effects of sorafenib on 
TH levels in patients with hepatocellular carcinoma (HCC) and to evaluate 
possible mechanisms.
Design
We performed a prospective cohort study between 2009 and 2016.
Setting
This study was conducted at a tertiary referral center.
Patients
This study included 57 consecutive patients with HCC who were treated with 
sorafenib.
Main Outcome Measure
Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels were 
measured every 6 weeks, and extensive thyroid function tests (TFTs) were 
measured before treatment (t0), after 6 weeks (t6), and at the end of therapy. 
The effect of sorafenib on TH transport by monocarboxylate transporter 
(MCT)8 or MCT10 was tested in transfected COS1 cells.
Results
Four patients (7%) developed thyroiditis. Among the other patients, 30% 
had elevation of TSH or FT4 above the normal range. Overall, between 
t0 and t6, mean TSH increased from 1.28 to 1.57 mU/L (p < 0.001) and 
mean FT4 from 18.4 to 21.2 pmol/L (p < 0.001). Simultaneously, the serum 
triiodothyronine (T3)/reverse triiodothyronine ratio and the (T3/thyroxine) 
×100 ratio decreased. Sorafenib decreased cellular T3 uptake by MCT8 and 
to a lesser extent by MCT10.
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Conclusions
These clinical data suggest that sorafenib affects TFTs on multiple levels. Our 
in vitro experiments suggest a possible role of sorafenib-induced inhibition 
of T3 transport into the cell by MCT8 and MCT10.
Abbreviations
CI, confidence interval; D3, deiodinase type 3; FT4, free thyroxine; HCC, 
hepatocellular carcinoma; HPT, hypothalamic-pituitary-thyroid; IQR, 
interquartile range; MCT, monocarboxylate transporter; NTI, nonthyroidal 
illness; PFS, progression-free survival; rT3, reverse triiodothyronine; t0, 
before treatment; t6, after 6 weeks of treatment; T3, triiodothyronine; T4, 
thyroxine; TH, thyroid hormone; TFT, thyroid function test; TKI, tyrosine kinase 
inhibitor; TPO-Ab, thyroid peroxidase antibody; TSH, thyroid-stimulating 
hormone; TSHR-Ab, thyroid-stimulating hormone receptor antibody; WHO, 
World Health Organization
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INTRODUCTION 
Several tyrosine kinase inhibitors (TKIs) are reported to be associated with 
changes in thyroid function tests (TFTs), of which sunitinib is the best studied 
(1). Sorafenib is used in the treatment of advanced hepatocellular carcinoma 
(HCC), renal cell carcinoma, and radioactive iodine-resistant differentiated 
thyroid carcinoma (DTC) (2-4). It has antiangiogenic, antiproliferative, and 
proapoptotic effects via multiple effector mechanisms, such as inhibition of 
the vascular endothelial growth factor receptor (5). In 2011, we reported on 
two patients with sorafenib-induced thyroiditis (6); since then, other cases 
of sorafenib-induced thyroiditis have been described (7). Hypothyroidism 
and adverse effects, such as hypertension, are described to be associated 
with better prognosis among patients undergoing treatment with TKIs (8, 9). 
The incidence of sorafenib-induced hypothyroidism varies from 18% to 
50%. In previous studies (10-15), the diagnosis of sorafenib-induced 
hypothyroidism was only based on increased thyroid-stimulating hormone 
(TSH) levels. Patients with preceding thyroiditis, a different entity contributing 
to TSH increase, were not excluded. The pathogenesis of the rise in TSH in 
nonthyroiditis cases has not been elucidated.
A study in athyroid patients treated with sorafenib suggests that there may be 
an enhanced peripheral degradation of thyroid hormone (TH) by deiodinase 
type 3 (D3) (16). D3 expression has been described in other tumors (17). 
Inhibition of TH uptake via the cellular TH transporter [monocarboxylate 
transporter (MCT) 8] has been shown for sunitinib, imatinib, dasatinib, and 
bosutinib, but this has not been studied for sorafenib (18). The effects of TKIs 
on MCT10-mediated TH uptake into cells are, to the best of our knowledge, 
unknown.
The aim of the present study was to explore the effects of sorafenib on the 
hypothalamic-pituitary-thyroid (HPT) axis and peripheral TH metabolism 
by assessing detailed TFTs in patients without known thyroid disease. By 
studying patients with intact thyroid glands, we were able to study effects on 
the HPT axis at different levels. In addition, we studied the consequences of 
sorafenib on cellular triiodothyronine (T3) uptake in vitro.
PATIENTS AND METHODS
Patient characteristics
We prospectively studied consecutive patients with progressive metastatic 
HCC and Child-Pugh A status who were treated with sorafenib between 
15689-CBeukhof_BNW.indd   42 05-10-18   09:55
3SORAFENIB-INDUCED THYROID HORMONE ALTERATIONS | 43
January 2007 and February 2016 in the Erasmus MC Cancer Institute, 
Rotterdam, Netherlands. Patients routinely started sorafenib at a dose of 
400 mg, which was increased in 1 month to 800 mg if deemed safe by the 
treating physician.
Routine TFT [TSH and free thyroxine (FT4)] levels were determined every 
6 weeks. In patients with enough material available, more extensive TFT 
levels were measured at baseline (t0), after 6 weeks (t6), and at the end 
of sorafenib therapy (Supplemental Figure 1). Patients with at least two 
laboratory evaluations were included in the study. The study was reviewed by 
the medical ethical committee of the Erasmus Medical Center (MEC-2015-
755); requirements to obtain informed consent were waved.
Clinical outcome
Baseline World Health Organization (WHO) performance status was assessed 
by the treating physician. Progression-free survival (PFS) was computed as 
the time from treatment initiation to disease progression according to the 
treating physician or death (19). Overall survival was computed as the time 
from treatment initiation to death. Adverse events were scored following 
Common Terminology Criteria for Adverse Events v4.0 (20). The incidence of 
all-grade hand foot skin reaction, hypertension, gastrointestinal complaints 
and thrombocytopenia was scored. Severe liver toxicity criteria were grade 
3 or 4 liver test disturbances in liver transaminases, γ-glutamyl transferase, 
and alkaline phosphatase or grade 2 bilirubin disturbances.
TFTs
Serum was centrifuged and stored at −20°C immediately after withdrawal. 
TSH (reference value, 0.4 to 4.3 mU/L) was measured using the Immulite 
2000 platform (Siemens, Erlangen, Germany). FT4 (reference value, 11 
to 25 pmol/L), thyroxine (T4) (reference value, 58 to 128 nmol/L), and 
T3 (reference value, 1.4 to 2.5 nmol/L) were measured using the Vitros 
ECi immunoanalyzer (Ortho-Clinical Diagnostics, Raritan, NJ). Reverse 
triiodothyronine (rT3) (reference value, 0.21 to 0.54 nmol/L) was measured 
by in-house radioimmunoassay (21). Intra- and interassay variability 
coefficients of all assays were <11% (22). T3/rT3 (reference value, 2.65 to 
7.65) and rT3/T4 ×100 (reference value, 1.4 to 3.1) ratios were calculated as a 
proxy for peripheral deiodinase activity. Thyroid peroxidase antibodies (TPO-
Abs) (reference value, <100 IU/mL) were measured using the ImmunoCAP 
method (Phadia 250, Uppsala, Sweden). TSH receptor antibodies (TSHR-
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Abs) (reference value, <0.9 IU/L) were measured using the 2009-2012 TRAK 
LIA test (Brahms, Hennigsdorf, Germany) and the 2012-2015 TRAK Kryptor 
test (Brahms, Hennigsdorf, Germany), both WHO calibrated.
In vitro experiments
Effects of sorafenib on cellular uptake of T3 by human MCT8 and 
MCT10
Materials
Dulbecco’s phosphate-buffered saline with calcium and magnesium and 
GlutaMAX medium was obtained from Life Technologies (Bleiswijk, the 
Netherlands); culture dishes were from Corning (Schiphol, Netherlands); 
COS1 cells were from ATCC; bovine serum albumin, d-glucose, and T3 
were from Sigma-Aldrich (Zwijndrecht, Netherlands); transfection reagent 
X-tremeGENE9 were from Roche (Almere, Netherlands); and Na125I was from 
Perkin-Elmer (Groningen, Netherlands). [125I] T3 was prepared in our laboratory 
as described previously (22). The human MCT8 plasmid pcDNA3-hMCT8 and 
the human pcDNA3-hMCT10 were obtained as described elsewhere (22).
Cellular T3 uptake assays
COS1 cells were cultured in 24-well dishes with 0.5 mL Dulbecco’s modified 
Eagle medium/F12 + GlutaMAX medium containing 9% heat-inactivated fetal 
bovine serum, 2% penicillin/streptomycin, and 100 nM Na2SeO3. The cells 
were transfected with 100 ng empty pcDNA3, pcDNA3-hs MCT8, or pcDNA3-
MCT10 as described (23). T3 uptake was tested 48 hours after transfection. 
The cells were washed with the assay buffer (Dulbecco’s phosphate-buffered 
saline CaCl2 + MgCl2 + 0.1% bovine serum albumin + 0.1% glucose) and 
incubated for 5 minutes at 37°C with 1 nM (105 cpm) [125I] T3 and 0, 1, 10, 
or 100 µM sorafenib or 0, 1, 10, or 100 µM sunitinib in 0.5 mL assay buffer. 
After incubation, cells were washed with the assay buffer, lysed with 0.1 
M NaOH, and counted in a gamma counter. Data were obtained from three 
independent experiments, each performed in duplicate.
D3 activity in HCC samples
To exclude a major contribution of D3 expression in HCC to the altered 
TFTs, we measured D3 in six random patients from whom presorafenib HCC 
biopsies were available. Tumor tissue was fresh frozen and stored at −80°C 
until use. Thawed tissue samples were homogenized on ice in 10 volumes 
of PED10 buffer [0.05 M phosphate, 1 mM EDTA (pH 7.2), 10 mM DTT] using 
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a Polytron (Kinematica AG, Lucerne, Switzerland). Liver D3 activities were 
measured in duplicate by incubation of tissue homogenate (250 µg protein) 
for 120 minutes at 37°C with 1 nM [3′-125I]T3 (200,000 cpm) in 0.1 mL PED10 
as described elsewhere (24).
 
Statistical analysis
Normal distribution was evaluated using the Kolmogorov-Smirnov test. 
Residuals that were not normally distributed underwent natural logarithmic 
transformation, and if still skewed p-values were obtained via bootstrapping. 
Changes in TFTs were analyzed using a paired sample t test and if not normally 
distributed via a paired Wilcoxon signed-rank test. False discovery rate 
correction for multiple comparisons proposed by Benjamini (25) was applied. 
Logistic regression analysis was used to determine the association between 
change in TFTs and adverse effects. Median survival time was calculated 
using Kaplan Meier. A Cox proportional-hazard regression model adjusted 
for age, sex, WHO performance status, and average dose of sorafenib was 
used for the survival analysis. Proportional hazard and linearity assumptions 
were met. Two-way ANOVA with correction for repeated testing and post 
hoc analysis with a paired t test was used for sorafenib-induced inhibition of 
MCT8 and MCT10 transport of T3 into cells. Analyses were performed using 
SPSS version 23 (SPSS Inc., Chicago, IL).
RESULTS
Patient characteristics
Blood samples were collected from 57 patients with HCC. One patient had a 
TSH ≥10 mU/L before therapy and was therefore excluded from the analyses. 
None of the patients had pre-existent hyperthyroidism or hypothyroidism or 
used drugs interacting with TFTs, such as amiodarone and corticosteroids. 
This resulted in a final population of 56 patients, 44 (79%) of whom were 
male. Median age was 67 years [interquartile range (IQR), 57 to 71 years], 
and median WHO performance status was 1 (IQR, 1 to 2).
Thyroiditis
Four patients (7%) developed thyroid disease, with a pattern consistent 
with thyroiditis. Two of these patients have been reported in detail (6), with 
clearly elevated TPO-Ab (866 IU/mL) or TSHR-Ab (368 IU/L) levels at the 
time of thyroiditis. The other two patients also showed markedly increased 
TPO-Ab (1302 and 439 IU/mL) and TSHR-Ab (19 IU/L) levels at the time of 
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thyroiditis. Prospectively, both patients had elevated TPO-Ab levels before 
initiation of sorafenib treatment (140 and 343 IU/mL). In comparison, none 
of the 52 patients without thyroiditis had TPO-Abs, and only six patients 
(12%) showed mildly elevated TSHR-Ab levels (median, 1.7 IU/L; IQR, 1.1 to 
1.9). Ultrasound was not routinely performed prospectively.
Patients with thyroiditis had a median PFS of 16.3 months [95% confidence 
interval (CI), 6.1 to 26.5], and patients without thyroiditis had a median PFS 
of 4.9 months (95% CI, 2.3 to 7.5). Median overall survival was 18.5 months 
(95% CI, 0.1 to 43.5) vs. 10.8 months (95% CI, 8.6 to 13.0), respectively. We 
refrained from statistical analysis due to small patient number.
TFTs
Patients with thyroiditis were excluded from subsequent analyses of TFTs. 
Five out of the remaining 52 patients had mild subclinical baseline thyroid 
dysfunction: three patients had an isolated TSH elevation (5.14, 5.15, and 
6.59 mU/L), and two patients had a low TSH (0.25 and 0.39 mU/L).
In 14 of the other 47 patients (30%), TSH or FT4 became elevated above 
the upper limit of normal during treatment. Overall, TSH and FT4 levels rose 
significantly after start of treatment (Figure 1). Similarly, rT3 and T4 levels 
increased significantly (Table 1), whereas the serum T3/rT3 and T3/T4 ratios 
significantly decreased (Figure 1). These changes in TFTs occurred within 6 
weeks after start of treatment and persisted until the end of treatment.
Table 1. Change in TFTs
Reference 
values
t0
median [IQR]
t6
median [IQR]
p
t0 vs. t6
tω
median [IQR]
p
t0 vs. tω
Parameter
TSH(mU/L) 0.4-4.3 1.28[0.88- 1.66] 1.57[1.23-2.78] <0.001*** 1.68[1.03-2.65] <0.001***
FT4(pmol/L) 11-25 18.4[16.9-19.9] 21.2[18.5-24.8] <0.001*** 22.1[18.4-26.6] <0.001***
T4(nmol/L) 58-128 115[101-138] 121[98-152] 0.01* 123[108-144] 0.02*
T3(nmol/L) 1.43-2.51 2.12[1.87-2.39] 2.06[1.73-2.31] 0.12 1.95[1.75-2.17] 0.001**
rT3(nmol/L) 0.21-0.54 0.41[0.36-0.59] 0.57[0.41-0.73] <0.001*** 0.58[0.46-0.76] <0.001***
Ratio 
T3/rT3 2.65-7.65 4.84[3.74-5.84] 3.68[2.63-5.01] <0.001*** 3.40[2.73-3.99] <0.001***
T3/T4x100 1.42-3.05 1.88[1.56-2.05] 1.58[1.41-2.03] 0.003** 1.55[1.29-1.81] <0.001***
Changes in TFT were analyzed using a paired sample t test and if not normally distributed via 
a paired Wilcoxon signed-rank test. False discovery rate correction for multiple comparisons 
proposed by Benjamini (25) was applied. IQR, interquartile range; *, p<0.05; ** , p<0.01; ***, 
p<0.001
N, number of patients; t0, before treatment; t6, after 6 weeks of treatment; tω, at the end of 
therapy; TFT, thyroid function tests
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Figure 1. Change in TFTs at t0, t6, and end of therapy (tω). Changes in TFTs were 
analyzed using a paired sample t test and if not normally distributed via a paired 
Wilcoxon signed-rank test. False discovery rate correction for multiple comparisons 
proposed by Benjamini (25) was applied. **, p < 0.01; ***, p < 0.001. 
In vitro experiments
Cellular T3 uptake mediated by MCT8 was significantly and dose-dependently 
inhibited by sorafenib, and very similar effects were observed with sunitinib 
(Figure 2). Both sorafenib and sunitinib had marginal effects on T3 uptake 
by control cells transfected with empty vector and on T3 uptake of cells 
transfected with MCT10. The short exposure of the cells to sorafenib and 
sunitinib (5 minutes) and the differential effects of the inhibitors on MCT8-
mediated vs. MCT10-mediated and background T3 uptake argue against an 
important contribution of possible cytotoxic effects of sorafenib and sunitinib 
in these experiments.
15689-CBeukhof_BNW.indd   47 05-10-18   09:55
48 | CHAPTER 3
Figure 2. Effects of sorafenib and sunitinib on T3 uptake by MCT8 or MCT10. 
Cells were incubated for 5 minutes with 1 nM [125I]T3 in the absence or presence 
of 1, 10, or 100 µM sorafenib or sunitinib as described in Materials and Methods. 
T3 uptake by cells transfected with MCT8 or MCT10 is corrected for T3 uptake by 
control cells transfected with empty vector (EV). T3 uptake is expressed as mean 
(standard error of mean) percentage of that in the absence of sorafenib or sunitinib 
of three independent experiments each performed in duplicate. Two-way ANOVA 
with correction for repeated testing showed significant change in T3 uptake after 
for sorafenib (p < 0.02) and sunitinib (p < 0.05). Post hoc, the significance of the 
difference between the effects of sorafenib or sunitinib on T3 uptake by MCT8 or 
MCT10 expressing cells vs. control cells is shown in the figure. This was tested by 
paired t test. *p < 0.05; **p < 0.01.
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The average D3 activity in the HCC tissue before sorafenib treatment was 1.17 
(IQR, <0.1 to 1.63) fmol/min/mg protein. This was not increased compared 
with the D3 activities in historical control livers (liver biopsies of patients 
who died of severe brain damage, taken within minutes after death) that we 
studied previously (26). 
Clinical outcome
An increase in TSH level was associated with a deterioration of PFS 
(Supplemental Table 1 ). This negative effect of TSH on PFS persisted 
in a multiple Cox-regression analysis with correction for age, sex, WHO 
performance status, and average dose of sorafenib (Figure 3). Adding 
response evaluation criteria in solid tumors (27) to the model did not 
influence the results. There was no association of FT4 with PFS. TSH showed 
the same trend for overall survival but did not reach statistical significance 
(Supplemental Table 1). Changes in TFTs were not correlated with adverse 
events (Supplemental Table 1).
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HR unadjusted:
1.26 (95% CI 1.04-1.53)
p=0.001**
HR adjusted:
1.27 (95% CI 1.05-1.53)
p=0.003**
Figure 3. The proportion of progression free survival by ΔTSH tertiles. Adjusted hazard 
ratio (HR) was calculated in a Cox proportional-hazard regression model adjusted for 
age, sex, WHO performance status, and average dose of sorafenib.
DISCUSSION
In this cohort of sorafenib-treated patients with HCC, we demonstrate that 
sorafenib affects TFTs via multiple mechanisms. Thyroiditis occurred in a 
small percentage of patients, whereas there was a combined increase in TSH 
15689-CBeukhof_BNW.indd   49 05-10-18   09:55
50 | CHAPTER 3
and FT4 in the remaining patients, which suggests a central effect on the HPT 
axis. Finally, there was a decrease in the T3/rT3 and T3/T4 ratios, suggesting 
additional effects on the peripheral metabolism of TH.
Thyroiditis
The incidence of thyroiditis was 7%, compared with 23% (14) and 5% (11) 
in other sorafenib cohorts and 40% (28) in patients treated with sunitinib. 
The incidence of subacute thyroiditis in the general population is much 
lower at around 12.1 cases per 100.000/y (29). However, we cannot draw 
conclusions on the basis of our observations because only four patients 
developed thyroiditis in this cohort.
Altered sensitivity of the HPT axis
Thirty percent of patients developed TSH or FT4 levels above the normal 
range during treatment. Median TSH and FT4 levels rose significantly. This 
simultaneous increase of TSH and FT4 suggests an altered setpoint of the 
HPT axis because an increase in FT4 would normally be accompanied by a 
decrease in TSH. For other TKIs, such as axitinib, an isolated increase in TSH 
accompanied by TH levels within the normal range has also been described 
(30). This altered setpoint could be explained at several levels because not 
only serum levels of FT3 and FT4 but also TH transport into the cell and 
intracellular deiodinase activity are determinants of TH action and the HPT 
axis setpoint (31).
Our in vitro experiments showed inhibition of MCT8-mediated T3 uptake by 
sorafenib. MCT8 is one of the transporters that is highly expressed in brain 
and pituitary (32), suggesting that sorafenib-induced interference with TH 
uptake by the hypothalamus or pituitary may be one of the mechanisms.
Alternatively, a sorafenib-induced decrease in deiodinase type 2 activity in the 
hypothalamus or pituitary (described later) would have similar consequences 
on the HPT axis setpoint. Alternative explanations could be interference with 
binding of T3 to its nuclear receptor, a diminished pituitary blood flow due to 
the antiangiogenic effects of sorafenib (33), or a reduced clearance of TSH 
(34). Future studies should investigate which mechanisms contribute to this 
altered sensitivity of the HPT axis.
Peripheral TH metabolism
There was a marked decrease in the serum T3/rT3 and T3/T4 ratios, 
suggesting additional changes in the peripheral metabolism of TH because 
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an isolated change in the HPT axis setpoint would not necessarily affect 
these ratios.
In previous experiments, we showed sunitinib-induced D3 activity in normal 
rat liver (33). The decreased T3/rT3 ratio observed in the current study 
fits with an induction of TH inactivation by D3, as has been described by 
Abdulrahman et al. (16). In the case of constant T4 production, increased 
D3 activity would not only lead to increased rT3 production but also to a 
decrease in T4 levels. However, in contrast to the study of Abdulrahman et 
al (16), which analyzed thyroidectomized patients on TSH-suppressive doses 
of levothyroxine, our study was performed in patients with intact thyroid 
glands. We did not only see effects on peripheral metabolism of TH but also 
a central effect on the pituitary, with an increase in TSH that would increase 
T4 production. This likely explains why T4 increases despite the decreased 
T3/rT3 ratio, which we assume to be caused by an increase in D3 activity. 
Similarly, the decreased T3/T4 ratio fits with a lower T4 to T3 conversion. 
The higher T4 production may explain why T3 levels remain stable despite 
this lower T4 to T3 conversion.
The increase in FT4 and the subsequent decrease in T3/T4 might suggest 
that other peripheral TH-metabolizing enzymes are also affected, such as a 
decrease in deiodinase type 1 or deiodinase type 2. In addition, uptake of TH 
into cells is rate limiting for subsequent metabolism. Because MCT8 is not 
only expressed in the brain but also in multiple other tissues (35) and MCT10 
is highly expressed in skeletal muscle, kidney, pancreas, and intestine (32) 
sorafenib-induced inhibition of T3 uptake by MCT8 and MCT10 may also 
have contributed to the alterations in peripheral metabolism of TH. Further 
experiments are needed to investigate the contribution of these different 
mechanisms in more detail.
Nonthyroidal illness (NTI) is not likely to be a major contributor because (1) 
changes in T3/rT3 and T3/T4 were most evident in the first weeks after start 
of treatment and not at the end of study (when the cancer was progressive) 
and (2) TSH and FT4 may remain normal in mild NTI, but the persistent and 
progressive increase in TSH and FT4 does not fit the pattern of NTI (36).
The changes in TH metabolism are independent of changes in binding 
proteins. A decrease in TH binding proteins would have led to a similar 
decrease in all iodothyronines, whereas we did see marked changes in the 
total T3/rT3 and rT3/T4 ratios, in which the binding proteins are both in the 
numerator and the denominator (37). Furthermore, measurements of FT4 
levels and total T4 levels changed in the same direction.
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Clinical outcome
In this study, we found that an increase in TSH is an independent negative 
prognostic marker for PFS. There was no association between FT4 and 
survival. In vivo, local hypothyroidism is known to be associated with HCC 
progression (38). In patients with other solid tumors, especially basal cell 
carcinoma, induction of D3 is associated with a hyperproliferative state 
and carcinogenesis (39). However, our results seem to be in contrast with 
two other studies in patients treated with sorafenib or sunitinib, where 
an increased TSH was negatively associated with tumor progression (10, 
13). It is not yet clear how to explain this inconsistency between these 
studies. However, there are a few differences between the studies: (1) in 
the previous studies, only patients with TSH levels above the normal range 
were investigated, whereas we assessed the absolute change of TSH on PFS 
and survival in all patients (including patients within the reference range); 
(2) in the previous studies, patients received levothyroxine, which may have 
affected tumor progression and makes it difficult to compare the results; and 
(3) in the other studies, patients with thyroiditis, who might have different 
prognostic profiles, were not excluded. Future studies are therefore needed 
to unravel if and how the effects of sorafenib on thyroid function can be 
regarded as a prognostic factor.
CONCLUSIONS
Our clinical data demonstrate that sorafenib-induced changes in TFTs are 
mediated at several levels, with in vitro experiments showing sorafenib-
induced inhibition of T3 transport into the cell by MCT8 and MCT10.
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Supplemental Figure 1.
Supplemental Table 1.
Delta TSH p Delta FT4 P
Prognosis HR (CI95%)
Death 1.16[0.98-1.37] 0.09 1.02[0.94-1.10] 0.79
Progression 1.26[1.04-1.53] 0.001** 0.96[0.87-1.04] 0.31
Adverse events OR (CI95%)
HFSR 1.14[0.76-1.70] 0.53 0.92[0.80-1.06] 0.26
Hypertension 1.00[0.56-1.76] 0.99 1.00[0.81-1.24] 0.97
Severe liver toxicity 0.74[0.49-1.12] 0.15 1.05[0.89-1.23] 0.59
Gastrointestinal 1.40[0.75-2.62] 0.29 0.92[0.78-1.08] 0.28
Thrombocytopenia 0.82[0.53-1.27] 0.37 0.97[0.85-1.12] 0.69
Adjusted hazard ratios (HR) were calculated in a cox proportional-hazard regression model 
adjusted for age, gender, world health organization performance status and average dose of 
sorafenib.
CI 95%, 95% confidence interval; Delta FT4, FT4 t6-FT4 t0; Delta TSH, TSH t6-TSH t0; HFSR, 
hand foot skin reaction; OR, odds ratio; t0, before treatment; t6, after 6 weeks of treatment; *, 
p<0.05; ** , p<0.01
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ABSTRACT
Background
Subclinical hypothyroidism is associated with dyslipidemia and atherosclerosis. 
Whether these effects are in part mediated via direct effects of thyrotropin 
(TSH) on peripheral thyroid hormone (TH) metabolism and/or concentrations 
of serum lipids is not clear.
Objective
This study examined whether TSH has direct effects on peripheral TH 
metabolism and serum lipids.
Methods
Eighty-two patients with differentiated thyroid cancer were retrospectively 
analyzed. All patients had undergone total thyroidectomy and 131I remnant 
ablation. During follow-up, two successive injections of recombinant human 
TSH (rhTSH) were administered to patients on a stable dose of levothyroxine. In 
all patients, TSH, thyroxine (T4), free T4 (fT4), triiodothyronine (T3), reverse 
T3 (rT3), total cholesterol, high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), and triglyceride 
levels were measured immediately before the first and approximately 72 
hours after the second injection of rhTSH.
Results
After rhTSH stimulation, T3 values decreased (from 1.91 to 1.81 nmol/L; p < 
0.001). T4, fT4, and rT3 did not change. After rhTSH, median apolipoprotein 
B increased from 0.90 to 0.92 g/L (p = 0.03), lipoprotein(a) from 0.21 to 
0.24 g/L (p < 0.001), and triglycerides from 1.98 to 2.50 mmol/L (p < 0.001). 
Serum high-density lipoprotein cholesterol decreased from 0.98 to 0.81 
mmol/L (p < 0.001). Multiple regression analysis showed that the changes in 
lipids were most closely associated with the decrease in T3 levels.
Conclusions
TSH has direct effects on peripheral TH metabolism by decreasing T3 levels 
in levothyroxine-treated thyroidectomized patients. This decrease in T3 
levels is accompanied by unfavorable changes in serum lipids.
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15689-CBeukhof_BNW.indd   61 05-10-18   09:55
62 | CHAPTER 4
INTRODUCTION
Subclinical hypothyroidism is defined by an elevated thyrotropin (thyroid 
stimulating hormone; TSH) with thyroxine (T4) and triiodothyronine (T3) 
levels within the normal range. This condition is associated with increased 
cardiovascular risk and elevated levels of total and low-density lipoprotein 
cholesterol (LDL-C) (1-7). It is likely that this association is caused by 
the slightly lower thyroid hormone (TH) levels in patients with subclinical 
hypothyroidism, rather than by the elevated TSH itself (8, 9). However, 
extrathyroidal TSH receptors have been shown in extraocular muscle, bone, 
fat tissue and liver, indicating that TSH may also have extrathyroidal effects 
(10-12). Studies in liver cells and rats suggest that TSH directly upregulates 
cholesterol synthesis via increased hepatic expression of 3-hydroxy-3-
methyl-glutaryl coenzyme A reductase (11, 12). This led to the hypothesis 
that part of the effects of subclinical hypothyroidism on lipid levels may also 
be mediated via direct effects of TSH. 
Approximately 20% of circulating T3 in healthy subjects is secreted by 
their thyroid gland. The major fraction is produced by deiodination of T4 in 
peripheral tissues (13). Intracellular T4 is converted to bioactive T3 by type 
1 and type 2 deiodinase (D1, D2). Inactivation of TH is mediated mainly by 
type 3 deiodinase (D3), which converts T4 to reverse T3 (rT3) and T3 to 
3,3’-diiodothyronine (14). Many factors have been identified that influence 
peripheral TH metabolism, such as starvation, medication, illness, and long-
term TSH suppressive (LT4) therapy (15, 16). Although TSH has been shown 
to increase hepatic conversion of T4 to T3 in perfused rat liver (17), direct 
effects of TSH on peripheral TH metabolism have not been reported in 
humans. 
Patients treated for differentiated thyroid cancer (DTC) by thyroidectomy 
and 131I ablation completely lack functional thyroid tissue. Consequently, 
all serum T3 in these patients results from conversion of T4 in peripheral 
tissues. In the follow-up of DTC, most patients may undergo a recombinant 
human TSH (rhTSH) stimulation test as part of a dynamic risk stratification. 
This stimulation test provides an ideal model to study the effects of TSH 
because of the constant T4 supply. The present study took advantage of 
this model to determine whether TSH has direct effects on peripheral TH 
metabolism and serum lipid levels. 
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METHODS 
Patients and treatment
Initial therapy consisted of total thyroidectomy and radioiodine (131I) remnant 
ablation. Patients were on TSH suppressive LT4 therapy aiming at a TSH level 
≤0.1 mU/L. Success of ablation was evaluated after about 6 months by means 
of rhTSH stimulated thyroglobulin measurements. On day 1, baseline non-
fasting blood was drawn for measurement of thyroid function tests (TFT) and 
lipids. Subsequently, 0.9  mg of rhTSH was administered intramuscularly on 
days 1 and 2. On day 5, a second nonfasting blood sample was drawn. 
Data of the rhTSH tests with a negative thyroglobulin response and negative 
thyroglobulin antibodies (TgAb) were retrospectively analyzed. The present 
study employed serum samples collected in an ethically approved study 
at the Erasmus MC (MEC 2012-561). Furthermore, leftover remnant sera 
from regular clinical procedures from the University Hospital Wuerzburg 
from the 2009–2013 time frame were analyzed. The study was performed 
in accordance with the German regulations on the use of serum sample 
remnants after diagnostic use. Samples were anonymized before analysis.
TFT
TFT and lipid levels before and after rhTSH administration were analyzed in 
the same run. Serum TSH (reference range 0.4–4.3 mIU/L), free T4 (fT4; 
reference range 11–25 pmol/L), thyroglobulin, and TgAb were measured 
as part of routine clinical practice. In Erasmus MC, TSH, thyroglobulin, and 
TgAb were measured using the Immulite 2000XPi platform (Siemens, Los 
Angeles, CA) with functional sensitivities of 0.01 mIU/L for TSH, 0.2 lg/L for 
thyroglobulin, and 2.2 IU/mL for TgAb. fT4 was measured using the Vitros 
ECiQ(Ortho-Clinical Diagnostics, Rochester, NY), with a functional sensitivity 
of 0.88 pmol/L. At the University Hospital Wuerzburg, TSH, fT4, as well as 
free T3 (fT3; reference range 2.7–7.6 pmol/L) were also measured using the 
Immulite 2000XPi platform (Siemens). The intra-assay coefficient of variation 
for fT3 was 3.2–7.0%. Serum thyroglobulin levels were determined using the 
immunoradiometric assay from BRAHMS (functional sensitivity of 0.4 lg/L) 
(9). TgAb levels were assessed using the direct chemoluminometric VARELISA 
method (Thermo Fisher Scientific, BRAHMS, Uppsala, Sweden). In all samples, 
total T4 (reference range 58–128 nmol/L) and T3 levels (reference range 
1.43–2.51 nmol/L) were measured using the Vitros ECiQ (Ortho-Clinical 
Diagnostics). Reverse T3 (reference range 0.21–0.54 nmol/L) was measured 
with an in-house radioimmunoassay (18) with an intra-assay coefficient of 
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variation of 4.2–8.7%. T3/T4 x100 (reference range 1.42–3.05), T3/rT3 
(reference range 2.65–7.65), and rT3/T4 x100 (reference range 0.15–0.44) 
ratios were calculated. These ratios are relatively insensitive to variations in 
protein binding and are considered to reflect peripheral deiodinase activities 
(19).
Lipids
Direct measurement of total cholesterol (reference range 2.9–6.5 mmol/L), 
LDL-C (reference range 2.59–4.12 mmol/L), high-density lipoprotein 
cholesterol (HDL-C; reference range 0.9–1.1 mmol/L), and triglycerides 
(reference range <2.0 mmol/L) were measured using standard laboratory 
techniques. Apolipoprotein B (apoB; reference range 0.60–1.33 g/L) was 
measured by immunoturbidimetry on a c311automatic analyzer (Roche 
Diagnostics, Basel, Switzerland). Plasma lipoprotein(a) (Lp(a); reference 
range <0.30 g/L) concentrations were measured using a particle-enhanced 
immunoturbidimetric assay, which is largely independent of the apo(a) 
kringel IV type 2 repeat number (DiaSys Diagnostic System, GmbH, Holzheim, 
Germany) (20). LDL-C was also calculated via the Friedewald formula [total 
cholesterol-HDL-C-(0.45 x triglycerides)] (21) and non-HDLC via the formula 
(total cholesterol – HDL-C) (21).
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics for Windows v23 
(IBM Corp., Armonk, NY). Changes in TFT and lipids were analyzed using 
the paired-sample t-test, and if not normally distributed via the paired 
Wilcoxon signed-rank test. Power calculations showed that with the largest 
sample that was available, using an alpha of 0.05 and a power of 80%, a 
statistically significant effect size of 0.3 would be able to be detected (22). 
Normal distribution was ascertained using the Kolmogorov–Smirnov test, and 
residuals that were not normally distributed were log transformed. Multiple 
linear regression models were used to study if the association of TSH with 
serum lipids was (partly) mediated via changes in T3. Multiple comparisons 
were accounted for using the Benjamini and Hochberg false discovery 
procedure (23). Corrected p-values of <0.05 were considered significant.
RESULTS 
A total of 82 patients were studied: 56 patients from the University Hospital 
Wuerzburg and 26 patients from the Erasmus MC, Rotterdam. Thirty-two 
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patients were male. The median age was 44 years (interquartile range [IQR] 
= 35–59 years). None of the patients used medication that may influence TH 
metabolism (e.g., corticosteroids or amiodarone).
TH
As expected, serum TSH concentrations increased strongly after rhTSH 
injection (Table 1). Despite a constant dose of LT4 and stable concentrations 
of fT4 and rT3, T3 concentrations decreased after rhTSH injections (Table 1). 
The decrease in T3/T4 ratio and T3/rT3 ratio was mainly due to the decrease 
in T3 values (Table 1). Additionally, serum FT3, which was measured in the 
clinical routine in the 51 patients included in Wuerzburg, also decreased 
(Table 1). 
Table 1. Change in thyroid function tests after recombinant TSH stimulation
Variable reference value before rhTSH after rhTSH p
Parameter
TSH (mU/L)¥ 0.4-4.3 0.02 [0.01-1.00] 9.68 [7.30-14.6] <0.001***
FT4 (pmol/L)£ 11-25 23.6 (4.7) 23.6 (4.9) 0.41
T4 (nmol/L) £ 58-128 156 (41) 159 (43) 0.41
T3 (nmol/L) £ 1.43-2.51 1.91 (0.30) 1.81 (0.30) <0.001***
FT3 (pmol/L) £ 2.7-7.6 5.71 (1.34) 5.01 (1.05) <0.001***
rT3 (nmol/L) £ 0.21-0.54 0.53 (0.10) 0.53 (0.20) 0.90
Ratio
T3/T4x100¥ 1.42-3.05 1.22 [1.01-1.44] 1.13 [0.91-1.47] <0.001***
T3/rT3¥ 2.65-7.65 3.61 [2.96-4.63] 3.53 [2.75-4.34] 0.02**
rT3/T4x100¥ 0.15-0.44 0.33 [0.30-0.40] 0.33 [0.29-0.39] 0.90
Changes in TFT were analyzed using a paired sample t test and if not normally distributed via a 
paired Wilcoxon signed-rank test. False discovery rate correction for multiple comparisons was 
applied as proposed by Benjamini and Hochberg.
£,Mean (SD); ¥Median [IQR]; ** , p ≤ 0.01; ***, p ≤ 0.001
FT4, free thyroxine; IQR, interquartile range; SD, standard deviation; TFT, thyroid function test; 
TSH, thyroid stimulating hormone; rhTSH, recombinant TSH; T3, triiodothyronine; T4, thyroxine; 
rT3, reverse T3
Lipids 
Median apoB, Lp(a), non-HDL-C and triglycerides increased after rhTSH. 
Serum HDL-C decreased, whereas total cholesterol and LDL-C did not change 
(Table 2). 
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Table 2. Changes in non-fasting serum lipid concentrations after recombinant human 
TSH injection
Variable reference value before rhTSH after rhTSH p
apoB (g/L) £ 0.60-1.33 0.90 (0.03) 0.92 (0.03) <0.05*
Total cholesterol (mmol/L) £ 2.9-6.5 5.09 (0.14) 5.17 (0.13) 0.17
HDL-C (mmol/L) £ 0.9-1.1 0.98 (0.05) 0.81 (0.05) <0.001***
LDL-C (mmol/L) £ 2.59-4.12 2.90 (0.10) 2.84 (0.10) 0.40
Lp(a) (g/L) £ <0.30 0.21 (0.03) 0.24 (0.03) <0.001***
Triglycerides (mmol/L) £ <2.0 1.98 (0.14) 2.50 (0.16) <0.001***
LDL-C-Friedewald (mmol/L) £ 2.59-4.12 3.24 (0.13) 3.29 (0.13) 0.40
Non-HDL-C (mmol/L) £ 2.0-5.4 4.10 (0.15) 4.36 (0.15) <0.001***
Analysis by general linear model for repeated measurements was used and false discovery rate 
correction for multiple comparisons proposed by Benjamini and Hochberg was applied. 
Friedewald formula [total cholesterol-HDL-C-(0.45 x triglycerides); non-HDL-C formula (total 
cholesterol-HDL-C); £,Mean (SD); * , p ≤ 0.05; ***, p ≤ 0.001
apoB, Apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; Lp(a), Lipoprotein(a); SD, standard deviation; rhTSH, recombinant 
human TSH
Next, to determine if these changes in lipid levels could be attributed to 
direct effects of rhTSH or to its effects on serum T3 levels, serum T3 levels 
were added as a covariate to the multiple regression model. This showed that 
the changes in lipid levels were most closely associated with the changes in 
T3 and showed no evidence for an additional effect of rhTSH itself (Table 3).
Table 3. T3 adjusted change in non-fasting serum lipid concentrations after 
recombinant human TSH stimulation
Variable reference value before rhTSH after rhTSH adjusted p
apoB (g/L) £ 0.60-1.33 0.90 (0.03) 0.92 (0.03) 0.74
Total cholesterol (mmol/L) £ 2.9-6.5 5.09 (0.14) 5.17 (0.13) 0.74
HDL-C (mmol/L) £ 0.9-1.1 0.98 (0.05) 0.81 (0.05) 0.92
LDL-C (mmol/L) £ 2.59-4.12 2.90 (0.10) 2.84 (0.10) 0.92
Lp(a) (g/L) £ <0.30 0.21 (0.03) 0.24 (0.03) 0.74
Triglycerides (mmol/L) £ <2.0 1.98 (0.14) 2.50 (0.16) 0.92
LDL-C-Friedewald (mmol/L) £ 2.59-4.12 3.24 (0.13) 3.29 (0.13) 0.74
Non-HDL-C£ 2.0-5.4 4.10 (0.15) 4.36 (0.15) 0.74
Multiple regression analysis was performed in general linear model for repeated measurements, 
where changes in serum lipids were corrected for change in T3. False discovery rate correction 
for multiple comparisons was applied as proposed by Benjamini and Hochberg.
Friedewald formula [total cholesterol-HDL-C-(0.45 x triglycerides); non-HDL-C formula (total 
cholesterol-HDL-C); £,Mean (SD)
apoB, Apolipoprotein B; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; Lp(a), Lipoprotein(a); SD, standard deviation; rhTSH, recombinant 
human TSH; T3, triiodothyronine
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DISCUSSION 
To the best of the authors’ knowledge, this is the first study that provides 
evidence of a direct effect of TSH on peripheral TH metabolism in humans. 
The study was performed in a controlled setting during which patients 
were on a stable daily LT4 dosage. Administration of exogenous rhTSH led 
to a decrease in T3 and fT3 concentrations, and as a consequence also to 
decreased T3/T4 and T3/rT3 ratios. The results indicate that any TSH-related 
changes in lipid levels in vivo are mediated by a drop in (f)T3 concentrations 
when T3 is added as a covariate to the multiple regression model.
Peripheral TH metabolism
Unravelling the exact molecular mechanism causing the decreased T3 
concentrations requires further in vitro and in vivo studies. Potentially, the 
decrease in T3 concentrations can be explained by a decreased conversion of 
T4 to T3 by D1 or D2, or by an increased degradation of T3 to rT3 by D3. Since 
D2 may be more important than D1 for peripheral T3 production in humans, 
whereas D1 may be more important than D2 for rT3 degradation (24), it is 
speculated that a decrease in D2 activity is the most likely explanation for 
this reduction in T3 levels in the presence of unaltered rT3 levels. In the 
case of decreased D1 activity, an increase in rT3 concentrations would be 
expected as well (19, 25). An increased degradation by D3 would not only 
lead to lower concentrations of T3, but also to lower concentrations of T4 
given the constant LT4 dose, and an increase in rT3 concentrations (via the 
degradation of T4). 
Other explanations for the decrease in T3 concentrations upon rhTSH 
stimulation include an increased T3 degradation via nondeiodinative 
conjugation by forming T3 sulfate (26) and/or T3-glucuronide formation 
(27). These reactions would increase T3 solubility and biliary and urinary 
excretion. Also, altered T4 transport into T3 producing cells could explain the 
decrease in T3 concentrations, since this transport is the ratelimiting step for 
subsequent metabolism. 
Most circulating T3 is bound to proteins such as thyroxinebinding globulin, 
albumin, and transthyretin. Given that not only total T3, but also FT3 
concentrations decreased after rhTSH administration, it seems unlikely that 
the drop in serum T3 concentrations after rhTSH stimulation is caused by a 
change in T3 binding protein concentrations or affinity. 
A temporary change in diet after rhTSH injections might theoretically result 
in lower T3 levels (14), since fasting is a known cause of low T3 syndrome. 
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However, caloric restriction would decrease especially triglycerides (28). The 
increase in serum triglycerides that was identified and the lack of change in 
rT3 make this explanation highly unlikely. Furthermore, as most patients in 
this study underwent the procedure in an in-patient setting due to German 
nuclear medicine regulations, it was ascertained that patients did not fast 
between the two blood samples. A previous study in 15 DTC patients, did not 
show an effect of rhTSH administration on serum FT4 and FT3 concentrations, 
perhaps due to a lack of statistical power (29). 
Lipids
In the current study, short-term exposure to high TSH concentrations was 
associated with a decrease in (F)T3 concentrations and subsequently, a more 
unfavorable serum lipid profile. 
Hypothyroidism-induced changes in serum lipids are well established 
and characterized by elevated total cholesterol (6, 30), LDL-C (6, 31), 
triglycerides (32), Lp(a) (33), apoB (33) and decreased HDL-C (34). These 
changes are mediated via changes in cholesterol biosynthesis (3-hydroxy-3-
methylglutaryl-coenzym A), regulation of LDL-receptors (via sterol regulatory 
element-binding protein 2) (35), HDLmediated reverse cholesterol transport 
to the liver (36) and biliary cholesterol excretion (37, 38). The beneficial 
effect of TH on the lipid profile has led to the development of “liverspecific” 
thyromimetics such as Eprotirome. Eprotirome affects the T3 receptor-β 
isoform and results in a decrease in LDL-C, apoB, triglycerides, and Lp(a) (39). 
The current study, identified a decrease in T3 and a very similar diametrically 
opposite effect in apoB, triglycerides, and Lp(a), which seems to support a 
diminished T3 stimulation. 
LDL-C concentrations did not significantly change in this study, but 
non-HDL-C as well as apoB increased indicating increased levels of 
triglyceride-rich lipoproteins such as very -low-density lipoprotein (VLDL) 
or intermediatedensity lipoprotein. In line with this observation, others have 
shown a significant elevation of VLDL-C in patients with hypothyroidism 
(40). 
Potentially, the nonfasting status had an impact on these results. However, 
the identified changes in lipids are much larger and not in line with extensive 
observational data as summarized in the European Society of Cardiology 
guidelines (41). The most important differences are that the nonfasting 
status affects triglycerides, with an increase of 0.3 mmol/L versus an increase 
of 0.5 mmol/L in the current study, and the calculated non-HDL-C decreases 
by 0.2 mmol/L compared to an increase of 0.3 mmol/L in the current study. 
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Moreover, concentrations of HDL-C, apoB, and Lp(a) are not affected by 
fasting/nonfasting status in contrast to the current data. 
In the current study, all patients lacked functional thyroid tissue due to 
surgery and radioiodine ablation therapy. Therefore, the isolated effects of 
rhTSH were able to be studied in a very homogenous group with a constant 
LT4 supply. However, this study also has several limitations. First of all, in 
contrast to the short serum half-life of triglycerides (42) and VLDL-C (43) of 
only a few hours, the half-life of the other lipoproteins is as long as several 
days (44, 45). As a consequence, the steady state of serum concentration 
of most lipoproteins was not yet reached in this study. A maximal effect 
would probably be found after two weeks (46, 47), but the clearance rate 
and the effect of two injections of rhTSH versus continuous TSH stimulation 
are difficult to predict. The timeframe of five days was, however, sufficient 
to identify significant changes in the current study. A significant change in 
LDL clearance can occur within one day through a change in the activities 
of hepatic microsomal cholesterol 7alpha-hydroxylase and 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (48). Changes in Lp(a) concentrations 
over several days have been shown to be mainly determined by alterations in 
the rate of production in a kinetic study with radiolabeled Lp(a) (44). 
Second, statistical modeling can only give insight into possible associations. In 
other experiments, a direct effect of TSH on serum lipids has been suggested, 
but a possible confounding effect of a decrease in T3 concentrations has 
not been investigated (12, 49, 50). Further research with direct testing is 
necessary to unravel fully the pathophysiologic mechanisms of TSH and TH 
action on lipid metabolism. 
Third, the current study was performed in a specific patient population 
without a control group, and the data were, in part, collected retrospectively. 
Moreover, the possibility cannot formally be excluded that the rhTSH 
injections did not result, for example, in cytokine release and secondary 
changes in TH metabolism and action (51). Therefore, further studies in 
larger placebo-controlled cohorts including individuals other than thyroid 
cancer patients are required. 
CONCLUSION
RhTSH administration results in a decrease of serum T3 concentrations in 
LT4-treated thyroidectomized patients, which in turn affect serum lipid 
concentrations toward a more unfavorable profile. These data suggest a 
direct effect of TSH on peripheral T3 production. Replication is needed, and 
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future studies should further clarify by which molecular mechanisms TSH 
affects peripheral TH metabolism.
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ABSTRACT
Background
Hypothyroidism has been associated with impaired urinary concentrating 
ability. However, previous reports on thyroid hormone and urinary 
concentrating ability in humans only studied a limited number of patients 
with autoimmune thyroid disease or used healthy controls instead of paired 
analysis within the same patients.
Objective
To study the urinary concentrating ability in athyreotic patients with 
differentiated thyroid cancer on and off levothyroxine treatment as they are 
exposed to different thyroid states as part of their treatment in the absence 
of an autoimmune disease.
Design and methods
We studied 9 patients (mean age of 42.7 years) during severe hypothyroid 
state (withdrawal of levothyroxine before radioactive iodine therapy) and 
TSH suppressed state (on levothyroxine therapy). At these two points, serum 
and urine samples were collected after 14 hours of overnight thirsting. 
Results
Serum and urine osmolality were not significantly different between on and 
off levothyroxine treatment. Serum creatinine levels were significantly higher 
in patients off vs. on levothyroxine treatment (87.0 µmol/L vs. 71.0 µmol/L 
respectively; p = 0.044) and, correspondingly, the estimated glomerular 
filtration rate (eGFR) was significantly lower (89.6 mL/min vs. 93.1 mL/min 
respectively; p = 0.038). 
Conclusion
Short-term, severe hypothyroidism has no effect on urinary concentrating 
ability. Our study confirms the well-known effects of thyroid hormone on 
serum creatinine concentrations. 
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INTRODUCTION
Thyroid hormone (TH) is indispensable for the metabolism of all tissues. The 
importance of TH in normal physiology is well illustrated by primary thyroid 
diseases in which abnormal TH concentrations affect the function of several 
organs resulting in a variety of clinical symptoms (1). 
The ability to conserve water during periods of water deprivation is an important 
function of the kidney. Fluid deprivation increases serum osmolality and 
thereby causes a release of the antidiuretic hormone (arginine vasopressin 
(AVP)). In turn, in the principal cells of the collecting duct, vasopressin inserts 
pre-formed vesicles with the water channel aquaporin-2 into the apical 
plasma membrane to allow water reabsorption (2). The counter current 
mechanism creates the osmotic driving force for water reabsorption in the 
collecting duct. 
Hypothyroidism has been associated with impaired urinary concentrating 
capacity in animals and humans (3-6). Short-term hypothyroidism in rats 
results in a diminished medullary osmotic driving force for passive water 
movement across the collecting duct. This was associated with a significant 
decrease in the medullary sodium potassium chloride cotransporter type 2 
(NKCC2) (4). The impaired maximal urinary concentrating capacity in these 
rats with moderate hypothyroidism was readily reversed with TH replacement. 
On the other hand, long term hypothyroidism in rats resulted in an impaired 
urine dilution capacity after water loading as a result of the non-osmotic 
release of vasopressin (3). This defect was reversed by administering a 
vasopressin receptor antagonist.
Only a few studies on the urinary concentrating defect in hypothyroidism 
have been performed in patients with autoimmune thyroid disease (5, 6). 
A small study (n=4) of patients with hypothyroidism revealed a urinary 
concentrating defect after 16 hours of water deprivation (5). After adequate 
treatment with levothyroxine (LT4), this defect was corrected. Another study 
found similar defects in myxoedema patients (n=10) compared to healthy 
control subjects (n=15) after 16 hours of water restriction (6). Treatment 
of a small group of these patients (n=3) showed no improvement in urinary 
concentrating capacity. These studies on TH and urinary concentrating ability 
in humans only studied a very limited number of patients (5) or used healthy 
controls instead of paired analysis within the same patients (6). Furthermore, 
detailed thyroid function tests were not performed. 
The aim of this study was to extend the existing studies by investigating the 
urinary concentration ability for the first time in athyreotic patients, before 
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and after LT4 treatment. We therefore studied patients with differentiated 
thyroid cancer (DTC), as they are exposed to different thyroid states as part 
of their treatment in the absence of autoimmune disease. 
SUBJECTS AND METHODS
DTC patients, 18-65 years old, were recruited from the outpatient clinic of the 
Erasmus Medical Center Rotterdam, between November 2014 and October 
2015. Initial therapy consisted of total thyroidectomy. Patients were eligible 
for inclusion if they were scheduled for treatment with radioactive iodine 
(RAI); did not use drugs interfering with TH metabolism or drugs influencing 
urinary concentration capacity (e.g, diuretics, lithium, non-steroidal anti-
inflammatory drugs); did not have a urinary tract infection; had no history 
of diabetes insipidus, diabetes mellitus or adrenal insufficiency; and had 
an estimated glomerular filtration rate (eGFR) > 60 mL/min per 1.73 m2. 
Patients were instructed to restrain from water and food for 14 hours before 
their outpatient visit on two different occasions. The first measurement 
was scheduled after four weeks of TH withdrawal (before RAI therapy, to 
stimulate radioactive iodine uptake by malignant tissues) and the second 
a few months after restoring euthyroidism / TSH suppression. Our primary 
endpoint was the difference in urine osmolality between LT4 withdrawal and 
treatment. Peripheral blood samples and spot urine samples were obtained 
from all participants. The Medical Ethics Committee of the Erasmus Medical 
Center approved the study protocol (MEC-2014-134) and written informed 
consent was obtained from all study participants.
Laboratory measurements
Serum Free T4 (FT4) (reference range 11.0-25.0 pmol/L), total T4 (reference 
range 58.0-128.0 nmol/L) and total T3 (reference range 1.4-2.5 nmol/L) 
concentrations were measured by chemo luminescence assays (Vitros ECI 
Immunodiagnostic System; Ortho-Clinical Diagnostics, Rochester, MI). 
Serum TSH (reference range 0.4-4.3 mU/L) was measured by immunometric 
assay (Immulite 2000 XPi, Siemens, The Hague, the Netherlands). Serum and 
urine osmolality were measured by OM 6050 Osmo Station from A. Menarini 
Diagnostic and serum sodium, potassium, urea, creatinine, chloride and glucose 
concentrations were measured by Roche/Hitachi cobas c systems. The eGFR 
was computed automatically with the Chronic Kidney Disease Epidemiology 
Collaboration formula (CKD-EPI). Sodium, urea and creatinine concentrations 
were also measured in urine samples by Roche/Hitachi cobas c systems. 
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Statistical analysis
Based on the previous studies (5, 6), we postulated that a study in 10 
patients on and off LT4 treatment would be of sufficient sample size to find 
a significant difference in urine osmolality. Data were expressed as median 
with 25th and 75th percentiles. For paired analysis between patients on 
and off LT4 treatment the Wilcoxon signed rank test was used. We used 
SPSS 20.0 for Windows (SPSS, Inc., Chicago, IL, USA). The spearman rank 
correlation coefficient was calculated to evaluate the correlation between 
urine osmolality and age and thyroid function tests off and on LT4 treatment. 
A p-value < 0.05 was considered as statistically significant. 
RESULTS
We included 10 patients in the study. However, one of them started on 
treatment with a diuretic after the first visit and was therefore excluded. 
Nine patients with a mean age of 42.7 years [range 24-57 years] were 
analysed (Table 1). As expected, thyroid function tests were significantly 
different on and off LT4 treatment (Table 2), reaching very low levels of FT4 
(median 1.7 pmol/L) off LT4. Serum creatinine levels were significantly higher 
(87.0 vs. 71.0 µmol/L, p = 0.044) and the eGFR was significantly lower in 
hypothyroid state than in LT4 treated state (89.6 mL/min vs. 93.1 mL/min 
respectively; p = 0.038). Serum glucose levels were significantly lower 
during hypothyroidism (4.8 vs. 5.3 mmol/L, p = 0.011). Serum sodium and 
chloride levels were significantly higher during LT4 treatment than during 
hypothyroidism (143 vs. 141 mmol/L; p = 0.011 and 104.0 vs. 99.0 mmol/L; 
p = 0.007, respectively), while serum osmolality remained similar (287.0 on 
LT4 vs. 282.0 mOsm/kg off LT4; p = 0.09). 
Table 1. Characteristics of study participants
Sex N (%)
  Male 4 (44.4)
  Female 5 (55.6)
Age (years), mean (± SD) 42.7 (± 11.0)
Time between tests(days), median [25th-75th percentile] 124 [91-161]
Dose LT4 (µg), mean [range] 204.2 [150-325]
Dose LT4 (µg/kg), mean [range] 2.27 [1.6-3.1]
Diagnosis N (%)
  Papillary thyroid cancer 7 (82.5)
  Follicular thyroid cancer 2 (12.6)
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Table 2. Changes in thyroid function tests and serum electrolytes, creatinine and 
osmolality off and on LT4 treatment
Off LT4 LT4 treated p-value
TSH (mU/L) 68.4 [42.0-102.5] 0.049 [0.005-0.57] 0.008
FT4 (pmol/L) 1.7 [1.2-3.4] 24.1 [21.5-25.3] 0.008
Total T4 (nmol/L) 17.0 [14.0-28.0] 146.0 [132.0-170.5] 0.008
Total T3 (nmol/L) 0.7 [0.6-1.0] 2.1 [2.0-2.3] 0.008
Creatinine (µmol/L) 87.0 [76.5-92.0] 71.0 [67.5-89.5] 0.044
eGFR (mL/min) 89.6 [66.4-93.1] 93.1 [85.8-103.8] 0.038
Urea (mmol/L) 4.6 [3.7-5.1] 4.8 [4.1-5.2] 0.21
Sodium (mmol/L) 141.0 [138.5-141.5] 143.0 [142.0-144.5] 0.011
Glucose (mmol/L) 4.8 [4.5-5.1] 5.3 [4.9-5.6] 0.011
Potassium (mmol/L) 4.3 [4.2-4.5] 4.4 [4.1-4.6] 0.5
Chloride (mmol/L) 99.0 [97.5-101.5] 104.0 [102.5-104.5] 0.007
Osmolality (mOsm/kg) 282.0 [279.0-284.0] 287.0 [281.5-288.0] 0.09
Data are expressed as median [25th-75th percentile].
200
400
600
800
1000
hypothyroid LT4 treated
urine osmolality (mOsm/kg)
Oﬀ LT4 On LT4
Figure 1. Changes in urine osmolality off and on LT4 treatment. Each line between 
two dots represents a patient.
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Table 3. Changes in urine concentrations and osmolality
Off LT4 LT4 treated p-value
Osmolality (mOsm/kg) 630.0 [535.0-812.0] 765.0 [613.0-794.0] 0.17
Sodium (mmol/L) 84.0 [54.5-146.0] 141.0 [95.5-157.5] 0.21
Creatinine (mmol/L) 17.2 [12.3-28.5] 13.7 [12.1-20.6] 0.09
Sodium/ creatinine ratio 5.1 [1.9-10.8] 11.0 [5.1-12.0] 0.26
Urea (mmol/L) 258.0 [190.0-383.0] 328.0 [274.0-439.0] 0.09
Table 3 shows that urinary osmolality was not significantly different between patients on and off 
LT4 treatment (765.0 vs. 630.0 mOsm/kg, respectively; p = 0.17). Figure 1 shows the changes in 
urinary osmolality within each patient. There was also no significant difference in sodium, urea 
and creatinine levels in the urine samples. There was no correlation between urinary osmolality 
and age, TSH, FT4, total T4 and total T3 levels neither during hypothyroidism nor during LT4 
treatment (data not shown). 
Data are expressed as median [25th-75th percentile]. 
DISCUSSION
In this prospective study in athyreotic DTC patients there was neither a 
significant difference in urine osmolality nor in serum osmolality on and off 
LT4 treatment after a water and food deprivation test of 14 hours. Since 
we could not detect an impairment of urinary concentrating ability during 
severe hypothyroidism in our patients, we did not assess AVP and copeptin 
concentrations, a stable pre-pro-hormone of AVP. Our findings are in 
contrast with previously published studies in rats (4) and humans (5, 6). In 
these previous studies on urinary concentrating ability in humans, detailed 
thyroid function tests were not performed. The severity of hypothyroidism 
was predominantly based on clinical characteristics, which is not very precise 
(7). In the current study, we confirmed severe hypothyroidism biochemically 
with a median TSH level of 68 mU/L, and correspondingly low levels of FT4, 
total T4 and T3. Whereas previous studies were performed in patients with 
prolonged signs of hypothyroidism (i.e. myxedema), hypothyroidism in 
the current study existed only for four weeks. Although we cannot exclude 
that there would have been an impaired urinary concentrating ability after 
prolonged hypothyroidism, the current study excludes important acute 
consequences of altered thyroid hormone status. 
Another speculative explanation for our findings could be that our patients 
were treated with relatively high dosages of LT4 to establish TSH suppression 
(median TSH concentration of 0.049 mU/L) because of their thyroid cancer. 
Although our patients were not overtly thyreotoxic, high TH levels are 
associated with a hyperdynamic circulation including increased cardiac 
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output and blood pressure and decreased systemic vascular peripheral 
resistance (8). These systemic hemodynamic alterations are known to be 
associated with increased renal hemodynamics and urine flow which might 
have decreased the urine osmolality in our LT4 treated patients (9). This 
mechanism is supported by Wang et al, who observed in hyperthyroid 
rats a significant increase in solute excretion in the presence of an AVP 
independent downregulation of aquaporin water channels (10). In healthy 
human subjects, water deprivation causes the plasma osmolality to rise above 
280–290  mOsmol/kg, which leads to the release of AVP into the circulation. 
This results in increased water retention with a rise in urine osmolality to a 
maximum of 1000–1200 mOsmol/kg and restoration of plasma osmolality 
toward the reference range (11). Since the median urine osmolality was 
lower than 1000 mOsmol/kg in both thyroid states in our patients, one could 
speculate that there was a concentrating defect in both thyroid states and 
we were therefore not able to find a statistical significant difference in urine 
osmolality.
Serum creatinine levels were significantly higher in our patients during 
hypothyroidism than during LT4 treatment and, correspondingly, eGFR was 
significantly lower during hypothyroidism. This is in line with several case 
reports and case series (12-14). Previous detailed studies have shown that 
the changes in serum creatinine reflect actual changes in GFR instead of 
alterations in creatinine metabolism (15-17). 
A limitation of our study is the small number of patients, which is a 
consequence of the steadily growing number of DTC patients that are treated 
with RAI after preparation with recombinant TSH instead of LT4 withdrawal 
(18). A second limitation is the low iodine diet which patients had to adhere 
to in order to increase the effectiveness of RAI treatment. Although this diet 
is different from a “low-sodium” diet, any foods containing iodized salt and 
sea salt were not allowed (19). Therefore, we cannot exclude that this diet 
might have influenced the sodium and chloride levels and hence osmolality 
in our patients during hypothyroidism. Indeed, the significantly lower serum 
sodium (without development of hyponatremia) and chloride levels and the 
decreased urinary sodium/creatinine ratio off LT4 therapy, thus during the 
low iodine diet, support this notion. Similar results have been reported by 
Vannucci et al, who also showed significantly lower serum sodium levels off 
LT4 prior to ablative RAI treatment without any correlation between serum 
TSH and sodium levels, suggesting that the reduction in sodium levels is 
unrelated to the hypothyroid status (20). Finally, our study had an outpatient 
design which precludes strict control of adherence to the water deprivation 
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protocol. However, in general, an expectedly adequate serum osmolality was 
observed, indicating adequate water deprivation.
In conclusion, although previous studies have shown an impaired urinary 
concentrating ability in patients with myxedema, we did not find any evidence 
for impaired urinary concentrating ability in patients with short-term but 
severe hypothyroidism. 
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ABSTRACT
Background
Levothyroxine replacement treatment in hypothyroidism is unable to restore 
physiological thyroxine and triiodothyronine concentrations in serum 
and tissues completely. Normal serum thyroid stimulating hormone (TSH) 
concentrations reflect only pituitary euthyroidism and, therefore, novel 
biomarkers representing tissue-specific thyroid state are needed. MicroRNAs 
(miRNAs), small non-coding regulatory RNAs, exhibit tissue-specific 
expression patterns and can be detectable in serum. Previous studies have 
demonstrated differential expression of (precursors of) miRNAs in tissues 
under the influence of thyroid hormone. 
Objective
To study if serum miRNA profiles are changed in different thyroid states.
Design and methods
We studied 13 athyroid patients (6 males) during TSH suppressive therapy 
and after 4 weeks of thyroid hormone withdrawal. A magnetic bead capture 
system was used to isolate 384 defined miRNAs from serum. Subsequently, 
the TaqMan Array Card 3.0 platform was used for profiling after individual 
target amplification.
Results
Mean age of the subjects was 44.0 years (range 20-61 years). Median TSH 
levels were 88.9 mU/L during levothyroxine withdrawal and 0.006 mU/L 
during LT4 treatment with a median dosage of 2.1 µg/kg. After normalization 
to allow inter-sample analysis, a paired analysis did not demonstrate a 
significant difference in expression of any of the 384 miRNAs analyzed on 
and off LT4 treatment.
Conclusion
Although we previously showed an up-regulation of pri-miRNAs 133b and 
206 in hypothyroid state in skeletal muscle, the present study does not 
supply evidence that thyroid state also affects serum miRNAs in humans. 
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INTRODUCTION
Hypothyroidism is one of the most common endocrine disorders (1). In a 
subset (~10-15%) of patients, symptoms of hypothyroidism persist despite 
serum thyroid hormone concentrations within the laboratory reference 
range during levothyroxine (LT4) replacement therapy (2-4). One of the 
explanations for this impaired well-being might be the inadequacy of LT4 
treatment to restore physiological thyroxine (T4) and triiodothyronine (T3) 
concentrations, especially the T4/T3 ratio, in serum and tissues (5, 6). 
Studies in hypothyroid rats showed that LT4 monotherapy was unable to 
normalize concentrations of T4 and T3 in all tissues (7). Supra-physiological 
serum T4 concentrations had to be reached in most tissues to normalize 
tissue T3 concentrations and the LT4 dose required to normalize thyroid 
hormone concentrations was different for each tissue. 
Serum TSH concentrations, reflecting the pituitary feedback to thyroid 
hormone, is used in clinical practice to monitor LT4 treatment because it is 
the best available marker of thyroid state. However, although TSH typically 
reflects local T3 concentrations in the pituitary, it may not necessarily reflect 
local thyroid status in all tissues, especially when thyroid hormone production 
is not endogenously controlled, such as in athyreotic patients during LT4 
therapy (8, 9). For this reason, novel markers representing thyroid state of 
other tissues than the pituitary would be of great clinical relevance. 
MicroRNAs (miRNAs) are non-coding RNA molecules with a length of 
approximately 22 nucleotides, which predominantly post-transcriptionally 
repress the translation of miRNAs from target genes by binding to the 
3’UTR of messenger RNA (10-12). Overall, miRNAs exhibit tissue-specific 
expression patterns and each miRNA may affect the expression of hundreds 
of target genes. Recently, we reported on gene expression profiles in skeletal 
muscle of hypothyroid patients off and on LT4 therapy and found a large 
up-regulation in expression of the muscle-specific pri-miRNAs 133b and 206 
in hypothyroid state (13). This was supported by other studies that found 
an increase in expression of miRNAs- 1, 206, 133a and 133b in livers of 
hypothyroid mice compared to euthyroid controls (14). MiRNAs can also be 
present in the circulation and have been associated with a variety of diseases 
(15, 16). We therefore hypothesized that miRNA profiles in serum can also be 
influenced by thyroid state, and that miRNAs derived from different tissues 
potentially reflect tissue-specific differences in thyroid states. 
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MATERIALS AND METHODS
Patients
Patients with differentiated thyroid cancer (DTC) are exposed to different 
thyroid states as part of their treatment. These patients are subject to 
severe hypothyroidism before radioactive iodine (RAI) therapy to stimulate 
radioactive iodine uptake by malignant tissues, whereas they have relatively 
high thyroid hormone concentrations afterwards when receiving substitution 
therapy with LT4 to suppress TSH. As a consequence, these patients are 
an ideal model to study the consequences of different thyroid states 
longitudinally. Therefore, we used patients with DTC as a model to quantify 
serum levels of 384 miRNAs in different thyroid states. Since we were 
previously able to detect significant changes in numerous gene transcripts 
in peripheral blood as well as in muscle samples in respectively 8 and 10 
patients, while using a similar study design, we postulated that 13 patients 
would be enough to identify clinically relevant markers (13, 17). Using 
alpha=0.05 and power=80%, we would be able to detect a Cohen’s d effect 
size of 0.87, which is considered as a large effect.
13 DTC patients were consecutively recruited from the outpatient clinic of 
the Erasmus Medical Center, between May 1st 2013 and February 1st 2015. 
Patients were eligible for inclusion if they needed RAI therapy during LT4 
withdrawal according to the Dutch guidelines (18), had no other malignancies 
or an active inflammatory disease, and were between 18 and 80 years old.
The study protocol was approved by the Medical Ethics Committee of the 
Erasmus Medical Center (MEC 2012-561) and written informed consent was 
obtained from all study participants.
Thyroid function measurements
Peripheral blood samples were obtained in non-fasting conditions from all 
participants on and off LT4 treatment. Serum Free T4 (FT4, reference range 
11-25 pmol/L) and total T3 (reference range 1.4-2.5 nmol/L) concentrations 
were measured by chemoluminescence assays (Vitros ECI Immunodiagnostic 
System; Ortho-Clinical Diagnostics, Rochester, MI). Serum TSH concentration 
(reference range 0.4-4.3 mU/L) was determined by immunometric assay 
(Immulite 2000 XPi, Siemens, The Hague, the Netherlands). Serum samples 
were stored at −80°C until further analysis of miRNAs.
miRNA isolation from serum
The method of miRNA isolation and quantification has been previously 
described extensively (19). In short, the miRNAs were purified from serum 
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samples using TaqMan ABC Purification Kit – Human Panel A (Thermo Fisher, 
PN 4473087). These panels consist of superparamagnetic Dynabeads 
covalently bound to a unique set of 384 anti-miRNA oligonucleotides. The 
miRNAs match the miRNAs in Megaplex Pool described below. The panel 
includes exogenous and endogenous controls. Briefly, 100 µL of lysis buffer 
was added to 50 µL of serum. One µL of 1 nM of a non-human external control 
(ath-miRNA-159a) was added to monitor the extraction process, followed by 
the addition of 80 µL of beads (80 × 106 beads). The tubes were mixed for 40 
min at 1200 rpm and 30 °C, the beads were isolated using a magnetic bead 
separator, and washed three times with wash buffer. The bound miRNAs were 
eluted from the beads with 100 µL elution buffer and incubated at 70 °C for 3 
min. The eluted miRNA pool was stored at −80 °C until ready to use.
For miRNA profiling, Megaplex Primer Pool A was used in conjunction with 
the matching TaqMan miRNA Array Card A. All reagents were purchased from 
Thermo Fisher/Life Technologies (Bleiswijk, NL). Briefly, 3 µL of the miRNA 
sample isolated with the ABC kit was reverse transcribed with the Megaplex 
RT Primer Pool A (PN 4399966) in a 8 µL final volume. The RT reaction was 
performed under thermal cycling (2 min at 16 °C, 1 min at 42 °C, 1 sec at 
50 °C, for 40 cycles) and the enzyme was inactivated by treatment for 5 
min at 85 °C. Four µL RT reaction was combined with its matching Megaplex 
PreAmp Primer Pool (PN 4399233) and TaqMan PreAmp Master Mix (PN 
4391128) in a final volume of 25 µL. Pre-amplification was done using the 
following cycling conditions: 10 min at 95 °C; 2 min at 55 °C; 2 min at 72 °C; 
15 sec at 95 °C, 4 min at 60 °C for 12 cycles; 99 °C for 10 min. The final pre-
amplification product was diluted 1:100 in 1X TaqMan Universal Master Mix 
(PN 4364341), then loaded onto the matching TaqMan MiRNA Array Card 
A (PN 4398965) and run on a TaqMan® 7900HT Fast Real-Time PCR System 
under universal cycling conditions.
miRNA quantification
Raw data files were imported and analyzed using ExpressionSuite v1.0.4 (Life 
Technologies, South San Francisco, CA, USA), a software data analysis tool 
that can easily import and analyze large raw data files. In these experiments, 
the quantification cycle (Cq) is defined as the fractional cycle at which the 
amplification plot crosses the fluorescence threshold (Ct). The baseline was 
set automatically and the threshold was manually set at 0.2 and adjusted 
whenever appropriate to get an intersection in the exponential part of the 
curve. To capture as many differentially expressed miRNAs as possible, the 
threshold was set at 40 instead of 30–32 which is generally recommended by 
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Life Technologies for relatively high miRNA levels. Undetermined values were 
replaced with the maximal number of cycles (=40) (20). The non-human 
external control (ath-miRNA 159a) differed between the serum samples with 
Cq values ranging between 23.0 and 26.9 (mean Cq value 24.4; SD 0.96). In 
previous studies using the same protocol, variation in spike-in controls has 
been reported to be similar (21). 
TaqMan miRNA array output data (sds files) were uploaded in the ThermoFisher 
Cloud App (https://www.thermofisher.com/mysso/loginDisplay) and analyzed 
using defined threshold settings for each individual miRNA. Cq values were 
exported and filtered for poor amplification performance (Amplification Status, 
Amp Score and Cq Conf, Supplemental Table 1). MiRNAs with average Cq 
values below 37 were included for statistical analysis. In addition, miRNAs were 
selected which had Cq values <37 in all samples, representing abundant miRNAs.
Software and statistics
In order to correct for differences in input, global normalization was 
performed (Supplemental Table 1) using QbasePlus (Biogazelle N.V., 
Zwijnaarde, Belgium) according to Mestdagh et al.(22). A second method 
for normalization, also using endogenous controls, was performed. Based on 
an established algorithm for stability analysis (Normfinder), miRNA 93 and 
miRNA 130a turned out to be the most stable combination of miRNAs with 
mean Cq values (±SD) of 28.3 (±0.58) and 30.5 (±0.6) respectively (23). 
Normalization was also performed using the mean of these normalizers. 
Heatmaps of miRNA data were generated in R using the “pheatmap” clustering 
software package using the default settings. The Wilcoxon signed rank test 
was used for paired comparison of miRNA levels (∆Cq) and thyroid function 
tests on and off LT4 treatment. Multiple comparison adjustment was applied 
using the FDR approach (24). 
RESULTS
Characteristics of 13 study patients are shown in Table 1. Mean age was 
44.0 years (±SD 11.1) and mean BMI was 30.0 kg/m2 (±SD 6.0). Three of the 
patients (subjects 11-13) were treated with remnant ablation RAI therapy 4 
weeks after thyroidectomy while the others were prepared for an extra RAI 
treatment by thyroid hormone withdrawal because of (suspicion of) residual 
or recurrent disease or positive anti-thyroglobulin (anti-Tg) antibodies. 
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Table 1. Baseline characteristics
Subject Age(years) Sex
BMI
(kg/m2)
Type of 
tumor
Comorbi-
dity
Number of 
RAI treat-
ments
Tg-off 
(µg/L)
Post-
therapy 131I 
scan
1 49 Male 25.8 PTC Pulmonary 
embolism 
1 3.9 No uptake
2 51 Female 34.1 PTC none 1 2.1 No uptake
3 34 Male 36.4 PTC none 4 517.0 Sacral 
metastasis
4 47 Female 32.9 PTC hypopara-
thyroidism
1 94.4 No uptake
5 50 Male 24.5 PTC none 3 5.6 LN
6 20 Female 20.7 PTC hypopara-
thyroidism
1 <0.9* No uptake
7 37 Female 24.6 PTC none 2 21.8 Mediastinal 
LN
8 39 Male 40.5 PTC none 3 12.9 No uptake
9 58 Female 29.0 FTC none 1 <0.9 Not 
performed
10 61 Female 26.7 PTC hyperten-
sion
1 21.6 No uptake
11 48 Female 35.1 PTC hyperten-
sion
0 <0.9* Thyroid 
remnant
12 45 Male 34.9 PTC hyperten-
sion
0 7.5 Thyroid 
remnant
13 33 Male 25.0 PTC none 0 <0.9* Thyroid 
remnant
PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma; BMI, body mass index; RAI, 
radioactive iodine; Tg, thyroglobulin; LN, lymph node; *anti-Tg positive
As expected, thyroid function tests were significantly different on and off LT4 
treatment (Table 2), reaching low levels of total T3 and FT4 with elevated 
TSH levels off LT4 replacement. 
Table 2. Thyroid function tests
Off LT4 On LT4 p
TSH (0.4-4.3 mU/L) 88.9 [56.5-118.5] 0.006 [0.004-0.015] 0.001
Total T3 (1.4-2.5 nmol/L) 0.64 [0.58-0.70] 2.13 [2.0-2.3] 0.001
Free T4 (11.0-25.0 pmol/L) 1.6 [0.4-1.8] 25.7 [22.4-29.3] 0.001
Dosage LT4 (µg/kg) 2.1 [1.9-2.6]
Time between tests, weeks (range) 24.7 [11.0-38.8]
Changes in thyroid function tests (normal range) off and on LT4 treatment. Data are presented 
as median with interquartile range. LT4, levothyroxine; TSH, thyroid stimulating hormone; T3, 
triiodothyronine.
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Figure 1. Heatmap showing the Cq values of all detectable miRNAs (n=135) in the 
different thyroid states. Clustering did not group the samples according to thyroid 
state. 
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Profiling of miRNAs 
Out of the 384 miRNAs analyzed, almost half showed very low to undetectable 
levels. After removing all miRNAs with average Cq values > 37, only 135 
miRNAs remained for analysis (Supplemental Table 1). Clustering of these 
globally normalized miRNAs did not group the samples according their 
thyroid state (Figure 1). The clustering of the abundant miRNAs (Cq values 
<37 in all samples, n=59) did not separate the samples according their thyroid 
state as well (Supplemental Figure 1). After calibration and normalization on 
the global mean, the statistical analysis revealed that none of the miRNAs 
was significantly altered between different thyroid states after correction for 
multiple testing (S1 Table). As a complementary approach, we normalized 
the dataset on the mean levels of two endogenous reference miRNAs 
(miRNA 93 and miRNA 130a). This confirmed the absence of any significant 
differences in levels of any of the miRNAs analyzed between thyroid states 
(Supplemental Table 1). 
Previously reported miRNAs
The profiles of miRNAs which have been previously reported to be differentially 
expressed in muscle and liver in hypothyroidism were evaluated (13, 14). The 
level of miRNA 1 and miRNA 133b were not amongst the 135 detectable 
miRNAs (S1 Table). MiRNA 206 was not on the card. MiRNA 133a showed 
a mean Cq value of 31.2 (±1.2) in hypothyroid state versus 31.3 (±1.7) in 
hyperthyroid state (not significantly different). 
DISCUSSION 
To our knowledge, this is the first study investigating a selected multi-target 
miRNA profile in serum of individual patients during (extreme) changes in 
thyroid states. Most studies on miRNAs in patients with thyroid disease have 
focused on thyroid cancer (25). A study by Yamada et al, reported several 
miRNA levels that were differently expressed in serum from patients with 
autoimmune thyroid disease compared with healthy subjects (26). They 
suggested that the underlying autoimmune condition was responsible for the 
observed changes since there was no association between the mentioned 
miRNAs and TSH levels. However they did not study the changes in miRNA 
expression after restoring euthyroidism (26). Another study demonstrated 
that different levels of circulating miRNAs are associated with intractable 
Graves’ disease compared with Graves’ disease in remission (27).
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In our study, we could not find significant changes in levels of serum miRNAs 
in athyroid hypothyroid patients on and off LT4 treatment, despite previous 
studies showing clear differences in (precursors of) miRNAs in different tissues 
(13, 14, 28). There are a number of possible explanations for our results. First, 
our sample size might have been too small to discover significant changes 
in miRNA levels. However, previously, in a cohort of similar size, microarray 
analysis revealed large differences between thyroid states in muscle samples, 
suggesting that the used sample size was sufficient if the differences would 
have been equally large and consistent (13). McDonald et al. found that 
assay imprecision (due to variability in the RNA extraction process and 
interassay imprecision) had significant effects on the reproducibility of miRNA 
measurements and concluded that only miRNAs that are extremely up- or 
downregulated will be suitable as clinical biomarkers (29). If there were such 
extremely up- or downregulated miRNAs they should have been detected in 
our sample size. Second, although it has been shown that miRNAs are present 
in human plasma and serum in a remarkably stable form that is protected 
from endogenous RNase activity (15), differences in the time between blood 
drawing and storage potentially impact on the miRNA levels released from 
blood cells, in particular if samples are stored over 24h (29). However, all 
our samples were stored at -80 °C within 2 to 4 hours of collection and 
therefore a significant effect on miRNA expression is not likely (30). Third, 
although after calibration, normalization of the data was performed using two 
different methods (based on the global mean and based on mean levels of 
two endogenous reference miRNAs) providing similar results, we cannot rule 
out that a variation in protocol efficiency might have influenced our results. 
Finally, although several studies have shown that thyroid hormones seem to 
regulate miRNA expression in several organs such as skeletal muscle, liver 
and heart, these changes in tissue miRNA expression may not be reflected in 
serum (13, 14, 28). It has to be mentioned that our previous study in muscle 
samples examined only precursors of mature miRNAs (pri-miRNAs) while our 
current study investigated the effects of TH on the levels of mature miRNAs. 
However, Dong et al. found significant decreases of both mature miRNAs and 
it’s corresponding precursor miRNAs in liver samples of hypothyroid mice 
compared to euthyroid controls (14). 
Our study has several strengths and limitations. A limitation of our study is 
that we only studied a selection of 384 miRNAs and we cannot rule out that 
other miRNAs, which were not included in our platform are influenced by 
thyroid state. For example, miRNA 206, of which the precursor pri-miRNA-206 
differed significantly in skeletal muscle, was not included in the current 
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platform. A possible confounder of our study is that we studied patients with 
DTC, while several miRNAs in serum have been postulated as biomarker for 
DTC (25). The levels of serum let-7e, miRNA-151-5p, microRNA-146b and 
miRNA-222 have been reported to be significantly increased in PTC patients 
relative to healthy controls (31, 32). Circulating levels of miRNA-146a-5p, 
miRNA-146b-5p, miRNA-221-3p, and miRNA-222-3p have been shown to 
decline after tumor excision (33). Although seven of our patients did not 
show any uptake on the post-therapy RAI scan and Tg-off levels were mostly 
low, some miRNAs theoretically could have been changed by the response 
of the tumor to RAI therapy or to the radiation it selves. Finally, although 
all patients with active inflammatory disease or other malignancies were 
excluded, some patients had comorbidities which might have affected their 
T3-dependent miRNA profile. Our study has several strengths as well. First, 
the study design included paired analyses, which has the advantage to 
reduce confounders. Second, we were able to study extreme differences in 
thyroid state in human subjects. Finally, we used a validated and widely used 
method to generate the serum miRNA profile (20, 34-36). 
In conclusion, although we previously showed regulation of pri-miRNAs by 
thyroid hormone in muscle samples, the present study using an extensive 
panel of 384 miRNAs does not supply evidence of regulation of mature 
miRNAs in serum by thyroid hormone. 
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Supplemental Table 1. Raw data and results of the statistical analysis with 
normalization on the global mean.
https://doi.org/10.1371/journal.pone.0194259.s001
Supplemental Figure 1. Heatmap showing the Cq values of the abundant miRNAs 
(Cq values <37 in all samples, n=59) in the different thyroid states. Clustering did not 
group the samples according to thyroid state.
15689-CBeukhof_BNW.indd   100 05-10-18   09:55
6SERUM MICRORNAS IN DIFFERENT THYROID STATES | 101
REFERENCES 
1. Vanderpump MP, Tunbridge WM. Epidemiology and prevention of clinical and subclinical 
hypothyroidism. Thyroid. 2002;12(10):839-47.
2. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological 
well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled 
community-based questionnaire study. Clinical endocrinology. 2002;57(5):577-85.
3. Wekking EM, Appelhof BC, Fliers E, Schene AH, Huyser J, Tijssen JG, et al. Cognitive 
functioning and well-being in euthyroid patients on thyroxine replacement therapy for 
primary hypothyroidism. Eur J Endocrinol. 2005;153(6):747-53.
4. Panicker V, Evans J, Bjoro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in 
relationship between anxiety, depression and thyroid function in subjects on and not on 
T4: findings from the HUNT study. Clin Endocrinol (Oxf). 2009;71(4):574-80.
5. Ladenson PW. Psychological wellbeing in patients. Clin Endocrinol (Oxf). 2002;57(5):575-
6.
6. Weetman AP. Whose thyroid hormone replacement is it anyway? Clin Endocrinol (Oxf). 
2006;64(3):231-3.
7. Escobar-Morreale HF, del Rey FE, Obregon MJ, de Escobar GM. Only the combined 
treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the 
thyroidectomized rat. Endocrinology. 1996;137(6):2490-502.
8. Gullo D, Latina A, Frasca F, Le Moli R, Pellegriti G, Vigneri R. Levothyroxine monotherapy 
cannot guarantee euthyroidism in all athyreotic patients. PLoS One. 2011;6(8):e22552.
9. Hoermann R, Midgley JE, Larisch R, Dietrich JW. Is pituitary TSH an adequate measure of 
thyroid hormone-controlled homoeostasis during thyroxine treatment? Eur J Endocrinol. 
2013;168(2):271-80.
10. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 
2004;116(2):281-97.
11. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-
33.
12. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. 
Cell. 2012;149(3):515-24.
13. Visser WE, Heemstra KA, Swagemakers SM, Ozgur Z, Corssmit EP, Burggraaf J, et al. 
Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin 
Endocrinol Metab. 2009;94(9):3487-96.
14. Dong H, Paquette M, Williams A, Zoeller RT, Wade M, Yauk C. Thyroid hormone may 
regulate mRNA abundance in liver by acting on microRNAs. PLoS One. 2010;5(8):e12136.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. 
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad 
Sci U S A. 2008;105(30):10513-8.
16. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS. Non-coding RNAs: regulators of disease. 
J Pathol. 2010;220(2):126-39.
17. Massolt ET, Meima ME, Swagemakers SMA, Leeuwenburgh S, van den Hout-van Vroonhoven 
M, Brigante G, et al. Thyroid State Regulates Gene Expression in Human Whole Blood. J 
Clin Endocrinol Metab. 2017.
18. Links TP, Huysmans DA, Smit JW, de Heide LJ, Hamming JF, Kievit J, et al. [Guideline 
‘Differentiated thyroid carcinoma’, including diagnosis of thyroid nodules]. Ned Tijdschr 
Geneeskd. 2007;151(32):1777-82.
15689-CBeukhof_BNW.indd   101 05-10-18   09:55
102 | CHAPTER 6
19. Rijlaarsdam MA, van Agthoven T, Gillis AJ, Patel S, Hayashibara K, Lee KY, et al. 
Identification of known and novel germ cell cancer-specific (embryonic) miRs in serum by 
high-throughput profiling. Andrology. 2015;3(1):85-91.
20. Gillis AJ, Rijlaarsdam MA, Eini R, Dorssers LC, Biermann K, Murray MJ, et al. Targeted serum 
miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a 
proof of principle. Mol Oncol. 2013;7(6):1083-92.
21. van Agthoven T, Looijenga LH. Accurate primary germ cell cancer diagnosis using serum 
based microRNA detection (ampTSmiR test). Oncotarget. 2016.
22. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. 
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 
2009;10(6):R64.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate 
normalization of real-time quantitative RT-PCR data by geometric averaging of multiple 
internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.
24. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false 
discovery rate controlling procedures. Bioinformatics. 2003;19(3):368-75.
25. Lodewijk L, Prins AM, Kist JW, Valk GD, Kranenburg O, Rinkes IH, et al. The value of miRNA 
in diagnosing thyroid cancer: a systematic review. Cancer Biomark. 2012;11(6):229-38.
26. Yamada H, Itoh M, Hiratsuka I, Hashimoto S. Circulating microRNAs in autoimmune thyroid 
diseases. Clin Endocrinol (Oxf). 2014;81(2):276-81.
27. Hiratsuka I, Yamada H, Munetsuna E, Hashimoto S, Itoh M. Circulating MicroRNAs in Graves’ 
Disease in Relation to Clinical Activity. Thyroid. 2016;26(10):1431-40.
28. Janssen R, Zuidwijk MJ, Kuster DW, Muller A, Simonides WS. Thyroid Hormone-Regulated 
Cardiac microRNAs are Predicted to Suppress Pathological Hypertrophic Signaling. Front 
Endocrinol (Lausanne). 2014;5:171.
29. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of 
circulating microRNA: preanalytical and analytical challenges. Clin Chem. 2011;57(6):833-
40.
30. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges 
in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014;18(3):371-90.
31. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, et al. Circulating microRNA profiles as potential 
biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 
2012;97(6):2084-92.
32. Lee JC, Zhao JT, Clifton-Bligh RJ, Gill A, Gundara JS, Ip JC, et al. MicroRNA-222 and 
microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. 
Cancer. 2013;119(24):4358-65.
33. Celano M, Rosignolo F, Maggisano V, Pecce V, Iannone M, Russo D, et al. MicroRNAs as 
Biomarkers in Thyroid Carcinoma. Int J Genomics. 2017;2017:6496570.
34. Carreras-Badosa G, Bonmati A, Ortega FJ, Mercader JM, Guindo-Martinez M, Torrents D, et 
al. Altered Circulating miRNA Expression Profile in Pregestational and Gestational Obesity. 
J Clin Endocrinol Metab. 2015;100(11):E1446-56.
35. Le Carre J, Lamon S, Leger B. Validation of a multiplex reverse transcription and pre-
amplification method using TaqMan((R)) MicroRNA assays. Front Genet. 2014;5:413.
36. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification 
of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.
15689-CBeukhof_BNW.indd   102 05-10-18   09:55
15689-CBeukhof_BNW.indd   103 05-10-18   09:55
15689-CBeukhof_BNW.indd   104 05-10-18   09:55
Beukhof CM, Brabander T, van Nederveen FH, 
van Velthuysen MLF, de Rijke YB, Hofland LJ, 
Franssen GJH, Fröberg LAC, Kam BLR, 
Visser WE, de Herder WW, Peeters RP
Submitted 
Peptide Receptor Radionuclide 
Therapy in patients with 
Medullary Thyroid Carcinoma: 
predictors and pitfalls
7CHAPTER
15689-CBeukhof_BNW.indd   105 05-10-18   09:55
106 | CHAPTER 7
ABSTRACT
Background
For progressive metastatic medullary thyroid carcinoma (MTC), the available 
treatment options with tyrosine kinase inhibitors result in grade 3-4 adverse 
events in a large number of patients. Peptide Receptor Radionuclide Therapy 
(PRRT), which has also been suggested to be a useful treatment for MTC is 
usually well tolerated, but evidence on its effectivity is very limited.
Objective
To evaluate the effectiveness of PRRT with 177Lu-octreotate for MTC. 
Methods
Retrospective evaluation of treatment effects of PRRT in a highly selected 
group of MTC patients, with progressive disease or refractory symptoms. 
In addition, a retrospective evaluation of uptake on historical 111In-DTPA-
octreotide scans was performed in patients with detectable tumor size >1cm. 
Results
Over the last 17 years, 10 MTC patients were treated with PRRT. Four out of 
10 patients showed stable disease at first follow-up (8 months after start of 
therapy) whereas the other 6 were progressive. Patients with stable disease 
were characterized by a combination of both a high uptake on 111In-DTPA-
octreotide scan (uptake grade ≥3) and a somatostatin receptor type 2a 
(SSTR2a) expression of the tumor by immunohistochemistry. Retrospective 
evaluation of historical 111In-DTPA-octreotide scans of 35 non-treated MTC 
patients revealed low uptake (uptake grade 1) in the vast majority of patients 
31/35 (89%) with intermediate uptake (uptake grade 2) in the remaining 
4/35 (11%). 
Conclusions
PRRT using 177Lu-octreotate could be considered as a treatment in those 
patients with high uptake on 111In-DTPA-octreotide scan (uptake grade 3) and 
SSTR2a expression in tumor histology. Since this high uptake was present in 
a very limited number of patients, this treatment is only suitable in a selected 
group of MTC patients.
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Abbreviations
Calcitonin, CT; CEA, carcinoembryonic antigen; CI, confidence interval; GEP-
NETs, gastroenteropancreatic neuroendocrine tumors; HR, hazard ratio; 
uptake grade 1= uptake < normal liver uptake; uptake grade 2= uptake equal 
to normal liver uptake; uptake grade 3= uptake > normal liver uptake; uptake 
grade 4= uptake > normal spleen or kidneys uptake; MTC, medullary thyroid 
carcinoma; OS, Overall Survival; P-NETs, pancreatic neuroendocrine tumors; 
PFS, progression-free survival; PR, partial response; PRRT, peptide receptor 
radionuclide therapy; RECIST, Response Evaluation Criteria In Solid Tumors; 
RET, rearranged during transfection; SSTR, somatostatin receptor; TKI, 
Tyrosine kinase inhibitor; WHO, world health organization
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INTRODUCTION
Patients and treatment
Medullary thyroid carcinoma (MTC), originating from calcitonin (CT)-
producing parafollicular C cells, is a rare form of thyroid cancer that 
accounts for less than 5% of thyroid carcinomas (1). In 25% of the cases, 
MTC is part of inherited disorders, such as multiple endocrine neoplasia 2a, 
2b or familial MTC involving RET germline mutations. Locally unresectable 
tumor or distant metastases have limited systemic treatment options (2, 3). 
Although the tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib 
have been shown to improve progression-free survival (PFS) [hazard ratio 
(HR), 0.46 and HR 0.28 respectively], grade 3 or 4 adverse events occur in 
a large number of patients (44% in vandetanib, 69% in cabozantinib) (3, 4). 
Therefore, alternative systemic treatment options with less side effects are 
needed. 
Somatostatin receptor (SSTR) expression has been reported in up to 85% 
of MTCs, particularly SSTR subtypes 2, 3 and 5 (5-7), with 49% of MTCs 
showing expression of the SSTR2a subtype (5). Somatostatin receptor 
scintigraphy with 111In-DTPA-octreotide (Octreoscan™), which has high 
affinity for SSTR2a, has been reported to show lesional uptake in 57-65% of 
MTC patients (8, 9). Therefore, targeting the tumor with a radionuclide using 
somatostatin analogs as a ligand seems to be an attractive option. 
In midgut neuroendocrine tumors, peptide receptor radionuclide therapy 
(PRRT) resulted in a PFS rate at 20 months of 65% vs. 11% in the control 
group (10). In this trial, baseline 111In-DTPA-octreotide uptake was positively 
correlated with remission rate (10). 
In MTC there is limited experience with PRRT treatment. A phase II trial in 31 
patients with 90Y-DOTATOC, which also targets SSSTR2a, reported a partial 
response (PR) in 29% of the patients (11). In a second trial treating 7 MTC 
patients with 177Lu-octreotate, 3 patients had PR, 3 patients had stable disease 
(SD) and 1 patient progressive disease (PD) (12). These results suggest 
that PRRT might be a useful treatment in patients with MTC, although the 
total number of treated patients is very limited so far. For that reason, we 
performed a retrospective evaluation of treatment with 177Lu-octreotate in 
our center, where it was used in a highly selected group of 10 MTC patients 
with progressive disease or refractory symptoms. In addition, we evaluated 
possible predictors and pitfalls of 177Lu-octreotate treatment in MTC. 
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METHODS 
We retrospectively studied 10 consecutive patients with histologically 
proven MTC. Patients treated with 177Lu-octreotate between 2000 and 2017 
had progressive metastatic MTC according to Response Evaluation Criteria 
In Solid Tumors 1.1 (13) (RECIST) or had clinically refractory disease. The 
study was approved by the Institutional Review Board of the Erasmus Medical 
Center and written informed consent was obtained from participants. 
We used the methods for 177Lu-octreotate therapy as described in detail 
previously (14). Patients received an average of 4 cycles of 177Lu-octreotate, 
up to a cumulative dose of 750 to 800 mCi, with an interval of 6 to 10 weeks 
(15, 16). Response to treatment was evaluated at a median of 8 months 
(3 months after the last cycle with 177Lu-octreotate) and subsequently at 
3 monthly follow-up visits, assessing clinical, biochemical and imaging 
parameters. The world health organization (WHO) performance status was 
scored at baseline and during follow-up by the treating physician. 
End points
PFS was computed as the time from treatment initiation to progression, 
assessed by objective tumor response RECIST 1.1 criteria, clinical disease 
progression according to the treating physician, death or until the last date 
of follow-up (13). Overall survival (OS) was computed as the time from 
treatment initiation to death, or until the last date of follow-up. Adverse 
events were scored according to Common Terminology Criteria for Adverse 
Events (17). 
111In-DTPA-octreotide scans
We retrospectively reviewed historical 111In-DTPA-octreotide scans between 
1999 and 2011 of non-treated MTC patients that were performed in 
metastatic MTC. Although not part of the regular follow-up of MTC (2), 111In-
DTPA-octreotide scans were performed for tumor staging in most of these 
patients. Uptake was scored according to the Krenning score (16, 18): uptake 
grade 1= uptake < normal liver uptake; uptake grade 2= uptake equal to 
normal liver uptake; uptake grade 3= uptake > normal liver uptake; uptake 
grade 4= uptake > normal spleen or kidneys uptake (Figure 1). 
Immunohistochemistry SSTR2a
SSTR2a immunohistochemistry was retrospectively performed in the patients 
treated with 177Lu-octreotate. Formalin fixed paraffin embedded (FFPE) 
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tissue slices of one or two tissue biopsies per patient were immunostained 
for SSTR2a using the Ventana BenchMark ULTRA stainer (Ventana, Tucson, 
Arizona, USA), according to the protocol provided by the manufacturer. The 
rabbit monoclonal anti-sst2 antibody (BioTrend, Köln, Germany) was used 
at a dilution of 1:25. Normal pancreatic tissue served as a positive control. 
SSTR2a expression was scored according to the percentage of cells with 
positive immunohistochemistry (0: absent staining; 1: weak staining <30% 
of cells; 2: moderate staining 30-60% cells; 3: strong staining >60% of cells). 
Scoring was done by two independent pathologists (F.H. N and M.F.V), who 
were blinded to each other’s findings and patient data. 
A B
Figure 1. The principle of Krenning uptake on 111In-DTPA-octreotide scans. A) MTC in 
neck region seems to have significant uptake. B) However when compared to normal 
liver uptake it is scored as Grade 2 uptake.
Laboratory measurements
Calcitonin (CT) and carcinoembryonic antigen (CEA) are useful tumor markers 
of residual disease and their doubling time is an indicator for prognosis (19). 
CT was measured on an Immulite 2000XPi immunoassay system (Siemens 
Healthcare Diagnostics, Los Angeles, USA) by chemoluminescence method. 
CEA was measured by an electrochemiluminescence immunoassay on a 
Cobas e601 immunoassay analyzer (Roche Diagnostics GmbH, Penzberg, 
Germany). The inter-day coefficient of variation of CT and CEA were 7.8% 
and 5%, respectively. 
Statistics 
We refrained from statistics due to limited patient number. PFS and OS was 
determined with Kaplan-Meier. 
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RESULTS 
Baseline 
Ten patients were treated with 177Lu-octreotate. They had a median age 62 
[range 19-75] years and 4/10 (40%) were male (Table 1). The indication for 
177Lu-octreotate was progressive MTC according to RECIST-criteria in 8/10 
(80%) of patients. One patient was treated for intracardial metastasis with 
biochemical progression and one patient for large cervical inoperable tumor 
load. None of the tested patients showed germline mutations in the RET 
proto-oncogene (Table 1). Eight out of 10 (80%) patients had a baseline 
WHO performance status of 1, whereas the other 2 treated patients had a 
WHO status of 3 (Table 1). Three out of 10 (30%) patients had an endocrine 
paraneoplastic syndrome due to tumor-produced adrenocorticotropic 
hormone (ACTH), resulting in ectopic Cushing’s disease, parathyroid 
hormone-related protein (PTH-rp) resulting in severe hypercalcemia and 
dopamine without clinical sequelae.
End points
Two patients showed PD during the third treatment cycle and were withheld 
from further treatment. In total, median PFS was 0.70 years [range 0.3-
12.0], 1 patient is still in follow-up with stable disease 1.6 years after start of 
treatment. In total, 6 out of 10 (60%) patients had tumor progression at first 
follow-up (8 months) after start of treatment. Four out of 10 (40%) patients 
had SD at first follow-up. This includes, the patient with intracardial tumor 
mass with SD at start of therapy. Overall, SD was maintained for a median 
of 1.4 years [range 0.7-12.0]. One patient had enduring ustained SD for 12 
years and died from an unrelated disease (fibrosarcoma). 
Overall median OS was 1.14 years [range 0.4-12.0]. Two patients are still 
alive at 1.4 and 1.6 years since start of PRRT. The median OS in SD patients 
was 1.8 years [0.8-12.0]. 
Baseline CT doubling time and CEA doubling time were not associated with 
SD or PD outcome at 8 months (Table 1). None of the patients showed a 
decrease in CT or CEA levels of ≥ 50% after treatment with 177Lu-octreotate. 
Three of the four patients with SD showed a 20-40% decrease of CT and/or 
CEA levels with sustained response. One out of these four patients showed 
an initial rise of tumor markers in the first 5 months, which was followed by 
a sustained decrease in both tumor markers. Four out of the 6 patients with 
PD showed loss of correlation with CT or CEA (no increase in tumor marker, 
despite progressive disease) (Table 2), which could be a pitfall in assessing 
response to therapy after PRRT. 
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Table 1. Patient characteristics 
Overall 
(N=10)
Stable disease 
(N=4)
Progressive disease 
(N=6)
Age years median [range] 63 [19-75] 69 [19-75] 60 [42-73]
Male N ( %) 4/10 (40%) 1/4 (25%) 3/6 (50%) 
RET 
Sporadic N (%) 6/10 (60%) 3/4 (75%) 3/6 (50%)
Unknown N (%) 4/10 (40%) 1/4 (25%) 3/6 (50%) 
Disease extent 
Moderate 8/10 (80%) 2/4 (50%) 6/6 (100%) 
Extensive 2/10 (20%) 2/4 (50%) 0/6 (0%) 
Tumormarkers 
Calcitonin DT years, [range] 2.4 [0.6-4.1] 0.8 [0.6-4.1] 2.6 [2.4-2.9]
CEA DT years, [range] 1.9 [0.6-7.4] 1.9 [1.2-2.1] 4.0 [0.6-7.4]
PRRT indication 
PD 8/10 (70%) 3/4 (75%) 5/6 (83%)
Tumor localization/ 
refractory symptoms£ 2/10 (30%) 1/4 (25%) 1/6 (17%)
WHO 
1 8/10 (80%) 3/4 (75%) 5/6 (83%) 
3 2/10 (20%) 1/4 (25%) 1/6 (17%)
Hormonal functioning ¥ 3/10 (30%) 1/4 (25%) 2/6 (33%) 
CEA, carcinoembryonic antigen; DT, doubling time; N, number; PRRT, peptide receptor 
radionuclide therapy; RET, rearranged during transfection; WHO, world health organization 
performance status
£ Intracardial metastasis and biochemical progression; inoperable cervical tumor load 
¥ ectopic ACTH; PTH-rp; dopamin 
Table 2. Clinical characteristics and outcome 
Overall 
(N=10)
Stable disease 
(N=4)
Progressive disease 
(N=6)
Uptake Grade ≥3 7/10 (70%) 4/4 (100%) 3/6 (50%)
Uptake Grade <3 3/10 (30%) 0/0 (0%) 3/6 (50%)
SSTR2a tumor expression 4/10 (40%) 4/4 (100%) 0/6 (0%)
Loss of correlation CEA/CT 4/6 (67%) 0/4 (0%) 4/6 (66%) 
Calcitonin, CT; CEA, carcinoembryonic antigen; Grade 3: uptake > normal liver uptake; N, number
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Predictors of response 
All 4 patients with SD showed high uptake on the 111In-DTPA-octreotide 
scans (uptake grade ≥ 3) and showed moderate to positive SSTR2a receptor 
expression on histological examination (Table 2). 
All patients with PD had negative tumor STTR2 expression in the tissue biopsy. 
Patients with PD had variable uptake on 111In-DTPA-octreotide scans, as well 
as on post therapy scans (Table 2). Two out of 6 patients (33%) showed 
uptake grade 3 on 111In-DTPA-octreotide scan. In one of these patients we 
identified a remarkable SSTR2a positive staining of tumor endothelium. In 1 
ot of the 6 patients (17%) non-homogenous uptake of 111In-DTPA-octreotide 
scan, with loss of uptake in some metastasis was observed. In the other 
patients, 1/6 (17%) showed uptake grade 2 and 2/6 (33%) showed uptake 
grade 1 (Figure 2).
Uptake Grade 1 Grade 2 Grade 3 Grade 4
PRRT N(%) 2/10 (20%) 1/10 (10%) 3/10 (30%) 4/10 (40%)
SRS N(%) 31/35 (89%) 4/35 (11%) 0/35 (0%) 0/35 (0%)
    
 ( )  (    
 ( )  (    
Uptake Grade 1 Grade 2 Grade 3 Grade 4
PRRT N(%) 2/10 (20%) 1/10 (10%) 3/10 (30%) 4/10 (40%)
SRS N(%) 31/35 (89%) 4/35 (11%) 0/35 (0%) 0/35 (0%)
t r  r  r  ra e 4
 ( ) /  ( ) /  ( ) /  ( ) 4/10 (40 )
 ( ) /  ( ) /  ( ) /  ( ) 0/35 (0 )
Uptake Grade 1 Grade 2 Grade 3 Grade 4
PR T N(%) 2/10 (20%) 1/10 (10%) 3/10 (30%) 4/10 (40%)
SRS N(%) 31/35 (89%) 4/35 (1 %) 0/35 (0%) 0/35 (0%)
Figure 2. Uptake on 111In-DTPA-octreotide scans in patients treated with PRRT and of 
35 non-treated patients with metastasized MTC. 
111In-DTPA-octreotide scans
None of the 35 retrospectively evaluated non-treated MTC patients had an 
111In-DTPA-octreotide scan with higher uptake in the metastases than in the 
liver (grade ≥3). Only 4/35 (11%) patients showed moderate uptake (grade 
2). In the majority of patients 31/35 (89%), the tumor was detectable, but 
uptake on  111In-DTPA-octreotide scan compared to liver uptake (Figure 2). 
Symptoms and adverse events 
There was no improvement of symptoms or paraneoplastic syndrome, neither 
in the stable disease patients nor in the progressive patients. Common grade 
1 side effects included diarrhea, fatigue, mild anorexia and mild hair loss, 
occurring in the majority of patients. Grade 2 diarrhea occurred in 1 out 
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of 10 patients. One patient developed grade 3 adverse event: hemoptysis, 
presumably due to progression of pulmonary metastasis. 
DISCUSSION
This study reports the results of 10 patients with metastasized MTC that 
were treated with PRRT using 177Lu-octreotate. Only 4 patients showed SD 
at first follow-up at 8 months after start of therapy. All of these 4 patients 
with SD showed high uptake (Krenning uptake grade ≥3) on the 111In-DTPA-
octreotide scan as well as SSTR2a receptor expression in the tumor upon 
immunohistochemistry staining, whereas none of the remaining 6 patients 
that had PD at first follow-up had such a combination of high uptake plus 
SSTR2a receptor expression in the tumor. 177Lu-octreotate was well tolerated, 
in accordance to previous publications (10).
Our results are similar to the results reported with 90Yttrium-labelled octreotide 
treatment (11), where partial response (PR), defined as any decrease in tumor 
marker, was reported in 9 out of 31 (29%) of patients compared to 3 out of 
10 (30%) of the patients in the present study.  Moreover, median OS was 
in a similar range, i.e. 1.3 years in patients treated with 90Yttrium-labelled 
octreotide vs. 1.14 years in our study population. However ,90Yttrium-
labelled octreotide is known to cause more severe hematological and renal 
side effects (11). 
The trial with PRRT in seven MTC patients by Vaisman et al. reported 3/7 
(42%) patients with PR, 3/7 (42%) patients with SD, and 1/7 (14%) with 
PD at 3 months follow-up (12). Although patient numbers are small, this 
suggests a better treatment response compared to the present study, where 
6/10 (60%) patients had PD. PFS was 6.38 years in the study by Vasiman 
et al. versus 0.70 years in our patient population. This might indicate that 
our study population included patients with more aggressive MTC. Several 
other study characteristics support this hypothesis. Firstly, the present study 
included 3/10 (30%) patients with paraneoplastic endocrine syndrome, which 
is a well-known poor prognostic factor (20). Secondly 4/10 (40%) patients 
showed loss of tumor marker expression, which is also associated with worse 
prognosis (21). And finally, our patients were much older (median age of 
62 years [range 19-75] in the current study versus 35 years [range 20-78] 
in the study by Vaisman et al.), which is relevant, as age is an important 
determinant of prognosis in MTC (22). 
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The hypothesis that our study population had a aggressive form of MTC is 
also supported by the very low PFS in the present study , 0.7 years compared 
to 1.6 years in the placebo group of the phase III trial of the ZETA study 
(vandetanib)) (4). Resuming, the above data suggest that patients treated 
with 177Lu-octreotate in this retrospective study were highly selected and had 
aggressive MTC tumors. 
Predictors of response 
All 4 patients with SD were characterized by high on  111In-DTPA-octreotide 
scan (grade ≥ 3) and SSTR2a tumor expression, which is in line with 
observations n GEP-NETs (15, 16). 
In the previously mentioned trial with 90Yttrium-labelled octreotide (12), 
tumor response did not correlate with 111In-DTPA-octreotide uptake. In that 
study only 2 out of 9 (22%) of the responders had a high uptake (grade >3) vs. 
6 out of 22 (27%) of the non-responders. However, response was based on 
tumor marker decrease and not scored according to RECIST criteria. SSTR2a 
staining on the tumor specimen was not performed. 
Importantly, our retrospective evaluation of historical 111In-DTPA-octreotide 
scans shows that only very few MTC patients have 111In-DTPA-octreotide 
scans with uptake grade ≥3. According to current European Neuroendocrine 
Tumor Society guidelines, high uptake on 111In-DTPA-octreotide scan is 
required to qualify for PRRT. Our data in MTC are in line with these diagnostic 
criteria for NET (23) and suggest that 177Lu-octreotate may only be a suitable 
treatment option for a very limited group of patients (Figure 1). Other papers 
have reported uptake in up to 65% of MTC patients, but none of these studies 
reported a formal uptake grade with comparison to hepatic uptake (8, 9). 
Surprisingly, we identified 3/6 (50%) patients in the PD group who had 
negative SSTR2a tumor staining upon immunohistochemistry, despite uptake 
grade ≥ 3 on 111In-DTPA-octreotide scan. This might be explained by non-
homogenous tumor expression of the SSTR2a receptor. Moreover, in one of 
these patients with PD, we identified SSTR2a immunohistochemistry uptake 
in the vascular endothelium instead of in the tumor itself, which may have 
resulted in uptake on 111In-DTPA-octreotide scan. Although vascular tissue 
usually predominantly expresses SSTR1, the vascular SSRT2a expression in 
this tissue sample could explain this finding (24). 
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In the present study SSTR2a expression was absent in all 6 patients with PD, 
which suggests that lack of SSTR2a expression in the tissue biopsy may be 
a bad prognostic sign in patients with MTC. This is in line with pancreatic 
NET (P-NETs) and GEP-NETs, where low SSTR2a tumor expression has been 
shown to be associated with poor outcome and more aggressive grades of 
tumor (25-27). In a retrospective study in 97 patients with MTC, SSTR2a 
expression was significantly correlated with the presence of lymph node 
metastasis. However, prognosis was not investigated (28). In human MTC 
cell line cultures, SSTR2a activation inhibited tumor cell proliferation (6). 
Limitations and future perspectives 
A limitation of the present study is the small number of patients. Despite 
this, as very limited data of PRRT in MTC patients are currently available, 
the present study provides valuable insights about which patients might 
potentially benefit from PRRT. In addition, it clearly illustrates that this therapy 
may only be suitable for a selected group of patients. In the present study, 
111In-DTPA-octreotide scans were used to evaluate SSTR2a uptake in 35 non-
treated patients, demonstrating very limited uptake in majority of patients. 
In the present study, 111In-DTPA-octreotide scans were used to evaluate 
SSTR2a uptake in 35 non-treated patients, demonstrating very limited 
uptake in majority of patients. The nowadays more commonly used 68Ga-
DOTATATE PET scans have better imaging properties due to pharmacological 
(higher affinity to SSTR2a), technical (eg. positron imaging, attenuation 
correction), as well as physical (higher gamma energies) differences and is 
useful for more precise staging of the patient (29,30). 68Ga-DOTATATE PET 
to evaluate eligibility for PRRT might result in more patients to be treated. 
However, as we did not observe significant differences in the pretreatment 
uptake on the 111In-DTPA-octreotide scan and post-therapy scan following 
PRRT, the amount of absorbed radiation dose to the tumors might be less 
than what would be needed for adequate treatment. 
Due to the low adverse events rate, 177Lu-octreotate could be considered a 
potential therapy in patients with both high uptake on pretherapy 111In-DTPA-
octreotide scan and as well as SSTR2a tumor expression. 
CONCLUSION
PRRT using 177Lu-octreotate could be considered in MTC patients with both a 
high tumor uptake (≥grade 3) on 111In-DTPA-octreotide scan as well as tumor 
SSTR2a receptor expression by immunohistochemistry. Further research is 
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needed to evaluate the effectiveness in these patients. Our retrospective 
data of 35 non-treated MTC patients, suggest that only minority of patients 
are eligible for 177Lu-octreotate therapy. 
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CASE REPORT
Patient A presented at the age of 15 to the emergency department with 
acute hip complaints after a fall. At the age of six years, nodules were 
removed from her tongue. Examination revealed a flexion, abduction and 
exorotation contracture of the left hip with a decreased range of motion. 
Radiology confirmed a slipped capital femoral epiphysis (SCFE) of the left hip 
(Figure 1). The SCFE was surgically treated with cannulated screw fixation. 
Peroperatively the blood pressure remained stable. A few months later the 
patient was referred to an ENT specialist because of a nodule in the neck. Fine 
needle aspiration of the lymph node revealed medullary thyroid carcinoma. 
The patient had thickened lips, nodules on the tongue and a marfanoid 
appearance (Figure 2). 
Patient B visited an orthopaedic surgeon at the age of 16 because of pain of 
the left hip on exertion for the last six months. On examination left hip flexion 
was diminished; however, abduction and adduction were within the normal 
range. Radiology of the left hip showed that the capital femoral epiphysis 
had slipped in a dorsomedial direction. Surgical treatment with a cannulated 
screw fixation was performed successfully. At the age of 17, the patient 
returned with an SCFE of the contralateral hip. Radiology confirmed a slip of 
the right epiphysis of the femoral head. No complications occurred during 
screw fixation. Preoperatively, a nodule in the thyroid had been noticed for 
which the patient was referred to a paediatrician. Thin needle biopsy showed 
no malignancy. Because of progressive growth of this tumour in the following 
years, which resulted in cosmetic complaints, the patient underwent a 
right hemi-thyroidectomy. Pathological examination surprisingly identified 
medullary thyroid carcinoma.
DIAGNOSIS 
SCFE can be a manifestation of the multiple endocrine neoplasia syndrome 
type 2 (MEN 2) (1). MEN 2 syndrome is subdivided into MEN 2a and MEN 2b 
and both have medullary thyroid carcinoma as the most common feature. 
However, hyperparathyroidism is characteristic for MEN 2a whereas patients 
with MEN 2b can be recognised by neurofibromas of the tongue and marfanoid 
habitus (2). The diagnosis of acute SCFE is easier than that of chronic SCFE 
(3).  Both disorders present with pain in the hip or with referred pain in 
the knee. Patients with acute SCFE typically have a contracture by flexion, 
abduction and exorotation. However, in patients with chronic SCFE the only 
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presenting symptom can be a mild limp (3). SCFE can be difficult to diagnose 
on anteroposterior radiographs (3). For chronic SCFE a lateral radiograph 
according to Lauenstein (hips in 90° flexion and maximal abduction) is advised 
(4).  SCFE often occurs bilaterally, therefore bilateral imaging at presentation 
and also during follow-up is indicated (4) . Treatment of acute and chronic 
SCFE is surgical (4).  
Awareness of the association between MEN 2 and SCFE could help to identify 
patients earlier. This is crucial in order to prevent metastatic medullary thyroid 
carcinoma. Pheochromocytoma can also be part of MEN 2 and could cause 
severe hypertensive crisis or arrhythmias perioperatively. Complications of 
SCFE are avascular necrosis, chondrolysis and coxarthrosis if the diagnosis 
is missed. 
Figure 1. A typical example of an acute slipped capital femoral epiphysis. 
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a)     b)  
Figure 2. a) A patient with neurofibromas of the tongue and eyelids, thick lips and 
marfanoid phenotype. b) Close-up of neurofibromas of the tongue (permission 
granted)
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THYROID HORMONE
TH is essential for the metabolism in virtually all cells of the human body, 
especially the brain, heart, adipose tissue and muscles (1). In this thesis several 
clinical external factors such as dietary intake of Se, medication such as TKI 
as well as internal factors such as direct effects of TSH on TH metabolism 
and on TH action were investigated. In addition, the consequences of TH 
action on renal concentration capacity, possible biomarkers of tissue TH 
concentrations, and a novel treatment for MTC were studied. 
Clinical factors affecting, thyroid hormone metabolism 
External Factors 
Nutritional trace element: Selenium
Many clinical factors are known to affect TH levels and metabolism. Dietary 
iodine deficiency, which is essential for normal TH synthesis, is still a 
concern in some developing countries (2). Se is another nutritional trace 
element that is essential for TH metabolism. TH action is regulated by the 
selenoenzymes D1-3, which all contain a selenocysteine in their catalytic 
centre (3). Extreme Se deficiency is associated with TH disturbances, Kashin-
Beck osteoarthropathy and bone malformations (4). It has been reported 
that European populations' dietary Se intake is low-normal. However, it is still 
a matter of debate whether subtle changes in Se status are associated with 
alterations in TH concentrations (5). This is especially relevant in the elderly 
who are at risk for malnutrition (6). In chapter 2, the results of a cohort 
analysis in 387 elderly men aged ≥70 years (Zoetermeer study) are reported. 
The effects of Se status on TH concentrations were studied. TFT (T4, T3, rT3 
and their ratios) were not affected by Se status in this population. Besides 
its role in TH metabolism, Se has many other actions including antioxidant 
defence and Se is associated with decreased inflammation in autoimmune 
disease (7). Se supplements significantly slowed down the progression of mild 
Graves’ ophthalmopathy (8). Moreover, a positive association between Se 
status and BMD has been described in postmenopausal women (9). However, 
data on the association of Se status and BMD in elderly men are lacking (10-
12). In chapter 2, the effects of Se status on BMD were evaluated. Se status 
was positively associated with BMD in healthy aging men. Although, women 
are known to be more susceptible to osteoporosis compared to men, but 
our current data demonstrate that Se status influences BMD in men as well. 
Interestingly, even in this population with borderline sufficient levels of Se, 
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there was a significant association between Se status and BMD independent 
of thyroid function. In vitro, the association between Se status and BMD could 
possibly be explained by the effects of Se on modulating oxidative stress and, 
secondary, osteoblast differentiation (13, 14). However, before establishing 
a causal relationship, the effect of Se supplementation on BMD and fractures 
should be investigated in a clinical trial in elderly patients. 
Medication: tyrosine kinase inhibitor sorafenib 
External factors, such as medication, can also affect TH metabolism. The 
effects of lithium, prednisone and amiodarone on TF are well known. Newer 
drugs, such as TKIs, have recently shown to be associated with changes 
in TFT as well (15). However, the underlying mechanisms are still largely 
unclear. Chapter 3 describes a retrospective cohort study in 57 patients with 
HCC treated with the TKI sorafenib. Our study demonstrates that sorafenib 
likely affects TFTs via multiple mechanisms. Thyroiditis occurred in 7% of the 
patients. Among the other patients, 30% had a combined increase of TSH and 
FT4 above the normal range, suggesting central adaptation of the HPT-axis. In 
addition, there was a marked decrease in the T3/rT3 and T3/T4 ratios during 
treatment with sorafenib. This could be explained by an effect of sorafenib 
on peripheral TH metabolism. Finally, it was demonstrated that sorafenib 
decreased the cellular uptake of TH via MCT8 and 10 in-vitro. In addition, the 
chapter shows that the increase in TSH is an independent negative prognostic 
marker for PFS. Future studies are needed to unravel if and how the effects 
of sorafenib on thyroid function can be regarded as a prognostic factor and 
how changes in TFTs are best managed. TH disturbances are also reported 
in patients treated with other therapeutics, especially immune modulating 
antibodies, such as check point inhibitors (16) and interferon alpha (17). It 
is important during the development of such therapeutic agents, to closely 
monitor for thyroid disturbances and other endocrinopathies, e.g. pituitary 
and adrenal dysfunction. If these are identified, their etiology should be 
further investigated for adequate management. 
Internal factors
Thyroid stimulating hormone
Besides external factors, TH metabolism is influenced by internal factors such 
as certain illnesses or pregnancy. However, it is not clear whether the internal 
factor TSH itself can have extra-thyroidal effects can change peripheral 
TH metabolism. Subclinical hypothyroidism is defined by an elevated TSH 
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level while T4 and T3 levels are within the reference range. This condition 
is associated with increased cardiovascular risk and elevated levels of total 
cholesterol and LDL-C (18-24). It is likely that this association is caused by 
slightly lower TH levels rather than by elevated TSH levels (25, 26). However, 
the presence of extra-thyroidal TSH receptors has been demonstrated in 
extraocular muscle, bone, fat tissue and liver, indicating that TSH may also 
have extra-thyroidal effects (27-29). In chapter 4 the possible direct effects 
of TSH on peripheral TH metabolism and serum lipids were studied in 81 
patients with DTC following successful radical thyroidectomy with subsequent 
131I ablation. During follow-up, thyroglobulin levels (indicating residual thyroid 
tissue which, is used as a tumor marker in these patients) were measured 
after 2 injections with rhTSH. In these patients we observed a significant 
decrease in T3 and FT3 from day 1 to day 5 despite a stable doses of LT4 
supplementation. In addition, median Apo B, Lp(a) and triglyceride levels 
increased significantly, whereas serum HDL-C decreased. Multiple regression 
analysis showed that the changes in lipids were most closely associated with 
the decrease in T3 levels. Further studies with direct testing and studies 
in larger placebo-controlled cohorts, including subjects without DTC, are 
needed to confirm these findings. For future research we recommend that 
changes in TH metabolism are taken into account, before conclusions about 
direct effects of TSH can be drawn. Besides, it still needs to be investigated 
whether sustained elevation of TSH also causes an enduring change in TH 
metabolism as well as atherogenic alterations in serum lipids in patients with 
intact thyroid glands. 
Consequences of thyroid hormone action 
Effects on renal concentration ability
Data on the urinary concentrating defects in hypothyroidism in humans 
are limited (30, 31). The few studies that are available investigated 
healthy controls or were performed in patients with autoimmune thyroid 
disease. Furthermore, detailed TFTs were not performed (32). Therefore, 
in chapter 5, we investigated the effect of acute hypothyroidism on renal 
concentration ability in 9 athyreotic patients, on and off treatment with LT4 
(i.e. during short-term severe hypothyroid state). Serum creatinine levels 
were significantly higher in patients off vs. on levothyroxine treatment. 
Correspondingly, the estimated glomerular filtration rates were significantly 
lower. This is in line with previous observations. No significant differences in 
serum and urine osmolality on and off levothyroxine treatment were found. 
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It cannot be excluded that the relatively high dosages of LT4 to attain TSH 
suppression in our patients have affected the results. Moreover, the effects on 
renal concentration ability in prolonged hypothyroidism might be different. 
However, the present study indicates that in states of acute hypothyroidism, 
for example following thyroidectomy in DTC patients, it is not necessary to 
take into account changes in urinary concentrating ability. 
Effects on miRNAs  
In clinical practice, LT4 substitution therapy is monitored by serum 
concentrations of TSH. Other markers, such as serum sex hormone binding 
globulin or creatine kinase, can be affected by TH, but these markers are not 
reliable in daily clinical practice. LT4 replacement therapy in hypothyroidism 
is generally insufficient to completely restore physiological T4 and T3 
concentrations in serum and tissues (33). By definition, normal serum TSH 
concentrations only reflect pituitary euthyroidism and, therefore, novel 
biomarkers representing tissue-specific thyroid status of other tissues are 
needed. MiRNAs, small non-coding regulatory RNAs, exhibit tissue-specific 
expression patterns and are detectable in serum. Previous studies have 
demonstrated differential expression of (precursors of) miRNAs in tissues, 
influenced by TH. In chapter 6, 384 defined miRNAs were studied in 13 
athyroid patients during TSH suppressive therapy and after 4 weeks of LT4 
withdrawal. The present study, did not provide evidence that serum miRNAs 
are useful markers for hypothyroidism in humans. Although previous studies 
have shown that THs regulate miRNA expression in several organs, including 
skeletal muscle, liver and heart, these changes in tissue miRNA expression 
may not be reflected in serum (34-36). A limitation of this study is that we 
studied a selection of 384 miRNAs and it cannot be ruled out that other 
miRNAs, that were not included in this platform, are influenced by thyroid 
state. Further research is needed to find biomarkers that reflect tissue 
specific thyroid status. 
Clinical factors affecting treatment outcome of thyroid diseases 
Medullary thyroid carcinoma
For progressive MTC, the available treatment with TKIs, frequently causes 
grade 3-4 adverse events, resulting in discontinuation of treatment in 12-
16% of patients, and additionally to dose reduction in 35-79% of patients 
(37, 38). Therefore, alternative systemic treatment options with less severe 
side effects are needed. Chapter 7 is dedicated to PRRT with 177Lu-octreotate 
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treatment for patients with MTC, which targets SSTR2a. In patients with 
inoperable metastatic midgut neuroendocrine tumors, PRRT with 177Lu-
octreotate, resulted in a significantly longer PFS rate at 20 months of 65.2% 
vs. 10.8% in the control group, who were treated with high doses of non-
radiolabeled somatostatin analogs (39). PRRT is generally well tolerated 
(39). There is very limited experience with PRRT treatment for MTC patients. 
Therefore, a retrospective evaluation of treatment with 177Lu-octreotate 
in MTC patients treated in our center was performed. PRRT with 177Lu-
octreotate was administered to 10 MTC patients with progressive disease 
or refractory symptoms. Our data indicate that PRRT for MTC could be 
considered as a treatment option in patients with both a high tumor uptake 
(≥ grade 3) on a 111In-DTPA-octreotide scan as well as SSTR2a expression 
by tumor immunohistochemistry. However, our data derived from 35 111In-
DTPA-octreotide scans performed in untreated patients with MTC suggest 
that only a minority of MTC patients are eligible for 177Lu-octreotate therapy. 
Larger numbers of MTC patients have to be treated with PRRT, before definite 
conclusions about the effectiveness of this therapy can be drawn. 
Strengths and weaknesses
The studies from this thesis were all conducted in a clinical setting. The 
etiology of frequently encountered clinical factors influencing TH action and 
metabolism were studied, while we also aimed to confirm these observations 
by direct testing in-vitro. We demonstrated, that a clinical model using 
paired analysis of patients on and off levothyroxine, and stimulation of rhTSH, 
provides new insights in TH action and metabolism. Our observations should 
be repeated in larger patient cohorts, in patients with an intact thyroid and 
in patients without suppressive TSH therapy. Besides, additional in-vitro 
experiments are necessary to further unravel the etiology of some of our 
observations. 
CONCLUSIONS
Several clinical factors e.g. dietary intake of Se, medication including the TKI 
sorafenib, but also internal factors, such as TSH stimulation, can affect TH 
metabolism. It is important to account for all these factors in the treatment 
of patients. For the correct interpretation of thyroid function, we need 
biomarkers other than TSH. This thesis does not support the use of miRNAs as 
a valuable biomarkers in hypothyroidism. Finally, in the treatment of thyroid 
diseases there is a constant search for maximal effective therapy while 
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avoiding side effects. This thesis shows that PRRT using 177Lu-octreotate can 
be useful in a highly selected subgroup of MTC patients with high uptake on 
111In-DTPA-octreotide scan as well as positive SSTR2a expression in tumor 
histology. 
FUTURE PERSPECTIVES 
This thesis shows the complexity of clinical factors affecting TH action and 
treatment outcome of thyroid diseases. Further research is needed to unravel 
pathophysiology, and to find new biomarkers and effective therapies that will 
be useful in day to day clinical practice.
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SUMMARY (ENGLISH)
Thyroid hormones are essential for normal functioning of the human body and 
almost all organ systems. Too little thyroid hormone (hypothyroidism) can 
result in fatigue, weight gain, cold intolerance, constipation, myopathy and 
also dyslipidemia and changes in renal function. Too much thyroid hormone 
secretion (hyperthyroidism) can result in weight loss, heat intolerance, 
frequent bowel movements and psychological changes. 
Chapter 1 provides a brief background about regulation of thyroid hormone 
synthesis by the hypothalamic-pituitary-thyroid axis, thyroid hormone 
metabolism by deiodinases and thyroid hormone action via thyroid hormone 
receptors and transporters. The treatment of thyroid diseases, including 
hypothyroidism, hyperthyroidism and thyroid cancer, is described. The 
outline of this thesis “clinical factors affecting thyroid hormone action and 
treatment outcome of thyroid diseases” is discussed. 
Clinical factors affecting thyroid hormone metabolism 
External Factors 
Nutritional trace element: selenium
Chapter 2 demonstrates that selenium status in a Dutch cohort of 387 
healthy elderly men (at least 70 years of age), is within the normal European 
marginally supplied range and does not affect thyroid function tests. It is 
however positively associated with bone mineral density independent of 
thyroid function. 
Medication: tyrosine kinase inhibitor sorafenib 
Chapter 3 shows in a retrospective cohort study in 57 patients with 
hepatocellular carcinoma, that sorafenib likely affects thyroid function tests 
via several mechanisms. Thyroiditis occurred in 7% of the patients. In the 
other patients we found a combined increase of TSH and FT4, which suggests 
a central adaptation of the hypothalamic-pituitary-thyroid axis. A marked 
decrease in the T3/rT3 ratio and T3/T4 ratios during treatment with sorafenib 
could be explained by the effect on peripheral thyroid hormone metabolism. 
Sorafenib decreased cellular uptake of thyroid hormone via monocarboxylate 
transporter 8 and in lesser extent monocarboxylate transporter 10 in-vitro. 
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Internal Factors
Thyroid stimulating hormone 
In chapter 4 direct effects of TSH on peripheral thyroid hormone metabolism 
and serum lipids were studied in 82 patients with differentiated thyroid 
carcinoma who had undergone total thyroidectomy and radioactive Iodine 
remnant ablation. Two successive injections of recombinant human TSH 
were administered to patients on a stable dose of levothyroxine. This 
resulted in a significant decrease in serum T3 and FT3 concentrations. It was 
accompanied by a more atherogenic serum lipid profile with a significant 
increase in median apolipoprotein B, lipoprotein(a) and triglycerides, and a 
decrease in high density lipoprotein cholesterol. Multiple regression analysis 
showed that the changes in lipids were most closely associated with the 
decrease in serum T3 levels.
Consequences of thyroid hormone action 
Effects on renal concentration ability
In chapter 5 we analyzed the effect of acute hypothyroidism on renal 
concentration ability, in 9 athyreotic patients with differentiated thyroid 
carcinoma, during withdrawal of levothyroxine. Serum and urine osmolality 
were not significantly different between patients on or off levothyroxine 
treatment. Besides our study confirms the well-known effects of thyroid 
hormone on serum creatinine concentrations.
Effects on MicroRNAs
In chapter 6 we searched for novel biomarkers representing thyroid state. We 
determined the effect of 4 weeks of levothyroxine withdrawal on microRNAs 
in the serum of 13 athyreotic patients with differentiated thyroid carcinoma 
prior to radioactive Iodine therapy. The present study shows that microRNAs 
are not affected by short term hypothyroidism and therefore does not 
support a role for microRNAs as biomarker for monitoring tissue-specific 
thyroid hormone status. 
Clinical factors affecting treatment outcome of thyroid diseases 
Medullary thyroid carcinoma 
In chapter 7 we retrospectively assessed the use of peptide receptor 
radionuclide therapy with 177Lu-octreotate in 10 patients with medullary 
thyroid carcinoma with progressive disease or refractory symptoms. Our 
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data indicate that peptide receptor radionuclide therapy for medullary 
thyroid carcinoma could be considered as a treatment option in patients with 
both a high tumor uptake (≥ grade 3) on a 111In-DTPA-octreotide scan as well 
as SSTR2a expression by tumor immunohistochemistry. However, our data 
derived from 35 111In-DTPA-octreotide scans performed in untreated patients 
with MTC suggest that only minority of MTC patients are eligible for 177Lu-
octreotate therapy. 
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SAMENVATTING (NEDERLANDS) 
Schildkierhormonen zijn essentieel voor het functioneren van het lichaam 
en vrijwel alle organen. Te weinig schildklierhormoon (hypothyreoïdie) leidt 
tot vermoeidheid, gewichtstoename, koude intolerantie, obstipatie, spierpijn 
en ook dyslipidemie (verstoring van vetten in bloed) en verandering van 
de nierfunctie. Teveel schildklierhormoon (hyperthyreoïdie) kan resulteren 
in gewichtsverlies, warmte-intolerantie, diarree en psychologische 
veranderingen. 
Hoofdstuk 1 geeft een korte achtergrond over regulatie van de 
schildklierhormoon balans door de hypothalamus-hypofyse-schildklier-as, 
schildklierhormoonmetabolisme door dejodases, en schildklierhormoonactie 
via schildklierhormoon receptoren en transporters. Introductie in de 
behandeling van schildklierziekten zoals hyperthyreoïdie, hypothyreoïdie en 
schildklierkanker wordt beschreven. De opzet van dit manuscript “klinische 
factoren van invloed op schildklierhormoonactie en de behandeluitkomst van 
schildklierziekten” wordt besproken. 
Klinische factoren van invloed op schildklierhormoon-
metabolisme 
Externe factoren 
Voeding spoorelement selenium: 
Hoofdstuk 2 laat zien dat seleniumstatus binnen de bekende Europese laag 
normale waarde valt en dat dit de schildklierfunctietesten niet beïnvloedt 
in een Nederlands cohort van 387 gezonde oudere mannen (≥70 jaar). 
Seleniumstatus is wel positief geassocieerd met botdichtheid, onafhankelijk 
van de schildklierfunctie.
Medicatie: tyrosine kinase remmer sorafenib 
Hoofdstuk 3 laat in een retrospectieve cohort studie in 57 patiënten met 
hepatocellulair carcinoom zien dat sorafenib schildkierfunctietesten via 
meer dan één mechanisme beïnvloedt. Thyreoïditis (schildklierontsteking) 
ontwikkelde zich in 7% van de patiënten. In de andere patiënten ontstond een 
gecombineerde verhoging van thyroïd stimulerend hormoon (TSH) en vrij 
schildklierhormoon (FT4), wat een centrale aanpassing van de hypothalamus-
hypofyse-schildkier-as suggereert. Een uitgesproken verhoging in T3/rT3 ratio 
en T3/T4 ratio gedurende de behandeling met sorafenib zou verklaard kunnen 
worden door beïnvloeding van het perifere schildklierhormoonmetabolisme. 
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In normale niercellen remt sorafenib de intracellulaire opname van 
schildkierhormoon via de schildklierhormoon transporter monocarboxylaat 
transporter 8 en in mindere mate monocarboxylaat transporter 10. 
Interne factoren 
Thyroïd stimulerend hormoon 
In hoofdstuk 4 worden de directe effecten van TSH op het perifere 
schildklierhormoonmetabolisme en serum lipiden onderzocht in 82 patiënten 
met een gedifferentieerd schildkliercarcinoom die een thyroïdectomie 
(operatieve verwijdering schildklier) en radioactief jodium behandeling 
hebben ondergaan. Twee injecties met recombinant humaan TSH tijdens 
stabiele levothyroxine suppletie werden toegediend. Dit resulteerde in 
significante afname van serum T3 en FT3 concentraties. Daarnaast ontstond 
een meer atherogeen serum lipiden profiel, met een significantie toename 
van apolipoproteïne B, lipoproteïne(a) en triglyceriden, met een daling van 
hoge-dichtheid lipoproteïne cholesterol. Multipele regressie analyse laat 
zien dat de verandering in serum lipiden geassocieerd was met de daling van 
de T3 waardes. 
Consequenties van schildkierhormoonactie 
Effecten op renale urineconcentratie 
In hoofdstuk 5 werden de effecten van acute hypothyreoïdie op renale 
urineconcentratie bestudeerd in 9 patiënten zonder schildklier (status na 
gedifferentieerd schildkliercarcinoom) tijdens levothyroxine suppletie en 
tijdens onttrekking van schildklierhormoon. Serum en urine osmolaliteit 
was niet significant verschillend met of zonder levothyroxine behandeling. 
De studie bevestigt de bekende effecten van schildklierhormoon op serum 
creatinine gehalte. 
Effecten op miroRNAs 
In hoofdstuk 6 werden nieuwe biomarkers voor schildklierhormoonstatus 
gezocht. Bij 13 patiënten, met in de voorgeschiedenis een gedifferentieerd 
schildkliercarcinoom, werd de verandering van serum microRNAs onderzocht, 
na 4 weken onttrekken van levothyroxine en voorafgaand aan radioactief 
jodiumbehandeling. De huidige studie toont aan dat hypothyreoïdie geen 
effect heeft op serum microRNAs in mensen en geen geschikte biomarker is 
voor weefsel specifieke schildkierhormoonstatus. 
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Klinische factoren van invloed op de behandeluitkomst van schildklier-
ziekten 
Medullair schildkliercarcinoom
In hoofdstuk 7 werd retrospectief het gebruik van peptide receptor 
radionuclide therapie met 177Lu-octreotaat in 10 patiënten met medullair 
schildkliercarcinoom met progressieve ziekte of refractaire symptomen 
onderzocht. Deze studie laat zien dat peptide receptor radionuclide 
behandeling overwogen kan worden bij patiënten met de combinatie van 
zowel hoge tumoropname op de 111In-DTPA-octreotide scan (graad ≥3) als 
positieve somatostatine receptor 2a tumor expressie bij immunohistochemie. 
Echter, uit 111In-DTPA-octreotide scans verricht bij 35 onbehandelde 
patiënten met medullair schildkiercarcinoom blijkt dat slechts de minderheid 
van patiënten voldoende tumoropname heeft om in aanmerking te komen 
voor peptide receptor radionuclide behandeling. 
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